_pmid,_doi,_publicationTitle,_year,_toolName,_toolType,_usageType,publicationId,resourceId,usageId
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,spheroid culture system,advanced_cellular_models,Experimental Usage,PUB36730269,REScbf4cfbd,USE7223b586
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,TAME chips,advanced_cellular_models,Experimental Usage,PUB40862755,RES02bbf891,USE4cef23bc
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,3D rBM overlay model,advanced_cellular_models,Experimental Usage,PUB39061138,RES7826f166,USEfc6b5b32
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,cNF organoids,advanced_cellular_models,Development,PUB38744290,RESe4a3a14d,USE7b3a0948
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,129T2/SvEmsJ::C57Bl/6NTac Nf1+/- and Nf1+/+,animal_models,Experimental Usage,PUB31545171,RES60a30c1c,USE62b54b5c
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,C57BL6/J Nf1+/−;Trp53+/−,animal_models,Experimental Usage,PUB32642734,RES6701a540,USE883ac5d3
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,Nf1 c.5425 C > T ; Arg1809Cys,animal_models,Experimental Usage,PUB35589737,RES5c29d488,USEee32315c
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,R681X Nf1,animal_models,Experimental Usage,PUB35589737,RES37d0d0f4,USEe0d24e96
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,Nf1 flox/flox ; Hoxb7-Cre,animal_models,Experimental Usage,PUB35589737,RESe1e3fe79,USE454f25f1
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,Nf1 f/neo ; hGFAP-Cre,animal_models,Experimental Usage,PUB35589737,RES9aecdcd6,USE64012ff3
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,Nf1-IF,animal_models,Experimental Usage,PUB38216123,RESae80970f,USE17b91ad5
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,Nf1-PS,animal_models,Experimental Usage,PUB38216123,RES95b54f21,USEc7739321
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,Nf1-IFPS,animal_models,Experimental Usage,PUB38216123,RES3a69c7aa,USE08e76506
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,Nf1(ob) (-/-),animal_models,Experimental Usage,PUB20200958,RES316daddd,USE908d4c4a
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,2.3-kb α1(I) collagen-cre Nf1 flox/flox,animal_models,Experimental Usage,PUB20200958,RES73ca456b,USE96e7bcdc
PMID:36890585 | PMID:40684195 | PMID:19191334 | PMID:21439418 | PMID:34935315 | PMID:25772366 | PMID:29847659 | PMID:29787563 | PMID:28525381 | PMID:25535838 | PMID:20200958,10.1186/s40478-023-01525-w | 10.1186/s40478-025-02075-z | 10.1002/glia.20845 | 10.1016/j.bone.2011.03.760 | 10.1117/1.JBO.26.12.125001 | 10.1016/j.celrep.2015.02.041 | 10.1167/iovs.17-22588 | 10.1371/journal.pone.0190001 | 10.18632/oncotarget.17589 | 10.7554/eLife.05151 | 10.1002/jbmr.42,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model. | Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma. | The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. | Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,Nf1 flox/flox,animal_models,Experimental Usage,PUB820f2963,RESbf0146a3,USE16e3b840
PMID:33078583 | PMID:21681782 | PMID:21551250 | PMID:21726432 | PMID:32839340 | PMID:18242513,10.1002/jcsm.12632 | 10.1002/ajh.22035 | 10.1158/0008-5472.CAN-10-4577 | 10.1186/1741-7015-9-82 | 10.1073/pnas.2008391117 | 10.1016/j.ccr.2008.01.003,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis. | Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype. | Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development. | MIA is a potential biomarker for tumour load in neurofibromatosis type 1. | Brain-wide structural and functional disruption in mice with oligodendrocyte-specific | The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,Nf1 flox,animal_models,Experimental Usage,PUB76829018,RESd390084f,USEf02486d3
PMID:32781282 | PMID:21199799 | PMID:8582272 | PMID:21949590 | PMID:40590220 | PMID:36890585 | PMID:40684195 | PMID:23071067 | PMID:26190969 | PMID:21439418 | PMID:25772366 | PMID:29847659 | PMID:18242513 | PMID:28525381 | PMID:16835260 | PMID:18632543,10.1016/j.trsl.2020.08.001 | 10.1158/0008-5472.CAN-10-2732 | 10.1242/dev.121.11.3583 | 10.2478/v10134-010-0025-8 | 10.1172/JCI188932 | 10.1186/s40478-023-01525-w | 10.1186/s40478-025-02075-z | 10.1158/0008-5472.CAN-12-1728 | 10.3389/fncel.2015.00234 | 10.1016/j.bone.2011.03.760 | 10.1016/j.celrep.2015.02.041 | 10.1167/iovs.17-22588 | 10.1016/j.ccr.2008.01.003 | 10.18632/oncotarget.17589 | 10.1093/hmg/ddl165 | 10.1001/jama.300.3.287,"Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1. | Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice. | Neurofibromin-deficient fibroblasts fail to form perineurium in vitro. | ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE. | A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms. | In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome. | Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. | The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation. | Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. | Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.",,Nf1+/-,animal_models,Experimental Usage,PUB51363032,RESd867fbf0,USE69442b09
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,y w Mer4,animal_models,Experimental Usage,PUB24595234,RES6e23a044,USE4ad67f29
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,4/FM7; T80-Gal4 y w Mer4,animal_models,Experimental Usage,PUB24595234,RES25632977,USEd4ac9002
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,PLP CreERT2; Nf1 f/−; ROSA-LacZ,animal_models,Experimental Usage,PUB30479396,RESe57e7070,USE953cb54b
PMID:34935315 | PMID:24465906 | PMID:21726432,10.1117/1.JBO.26.12.125001 | 10.1371/journal.pone.0086115 | 10.1186/1741-7015-9-82,"Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy. | Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1. | MIA is a potential biomarker for tumour load in neurofibromatosis type 1.",,Nf1Prx1-/-,animal_models,Experimental Usage,PUBad11fce9,RESe475a58f,USEe702e5a4
PMID:21963652 | PMID:19191334 | PMID:23225063 | PMID:25772366,10.1016/j.expneurol.2011.09.005 | 10.1002/glia.20845 | 10.1002/ana.23793 | 10.1016/j.celrep.2015.02.041,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,Nf1+/− GFAP CKO,animal_models,Experimental Usage,PUBa1435977,RESfd454e78,USE9ddffd20
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,Nf1(flox/-);Col2.3Cre(+),animal_models,Development,PUB21439418,RES22a66b69,USEb1691f85
PMID:38502231 | PMID:34010628,10.1172/JCI176748 | 10.1016/j.stem.2021.04.029,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,cisNP,animal_models,Experimental Usage,PUB7ceede6d,RES8010fe38,USE7c8422d8
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,y [1] sc[*] v [1] sev [21]; P{y[+t7.7] v[+t1.8] = TKO.GS01796}attP40,animal_models,Experimental Usage,PUB39129390,RES64a05ee5,USE460e3b8c
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,P{ KK101909 }VIE‐260B,animal_models,Experimental Usage,PUB39129390,RES01f5e8c7,USEd9d6d4ea
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,Nf1Dsk9/+,animal_models,Experimental Usage,PUB30571760,RESbb21f572,USEc043fbbf
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,P0SchΔ39-121,animal_models,Experimental Usage,PUB29408605,RESb805ba75,USEa2b8dd36
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,"Trp53, Nf1, Suz12 triple mutant",animal_models,Experimental Usage,PUB38931352,RES9f0896d4,USE33ec900f
PMID:33442015 | PMID:31527226 | PMID:33658640 | PMID:38127282,10.1038/s41591-020-01193-6 | 10.1158/1535-7163.MCT-19-0123 | 10.1038/s41416-021-01270-8 | 10.1158/1078-0432.CCR-23-2548,"Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.",,Nf1flox/flox;PostnCre,animal_models,Experimental Usage,PUB69ba4f7d,RES971399c4,USE3e7b5dac
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,NF1 fl/fl Tp53 fl/fl Eed fl/fl;Dhh-Cre,animal_models,Experimental Usage,PUB36322658,RESb8ec4fc0,USEa1609eeb
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,NF1 R1947/+,animal_models,Development,PUB37520682,RES136a6220,USEf08d1362
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,Nf1fl/fl,animal_models,Experimental Usage,PUB34040258,RES0178a4cc,USE7c7cbd03
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,OPG Nf1fl/mut (Nf1+/−),animal_models,Experimental Usage,PUB34040258,RESf2783b89,USE235d47c2
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,Nf1 hGFAP CKO,animal_models,Experimental Usage,PUB22901811,RES644113d0,USE7c4b5b58
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,Nf1 NcreER CKO,animal_models,Experimental Usage,PUB22901811,RES5b5f1511,USE7b86486c
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,Nf1 fcr,animal_models,Experimental Usage,PUB21681782,RES4cf34317,USEbe1b1ce6
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,NPcis,animal_models,Experimental Usage,PUB36730269,RESf5e1c690,USEde9653c8
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,"Nf1 flox/mut; GFAP-Cre, Nf1+/− GFAP CKO",animal_models,Experimental Usage,PUB20554030,RES9a06a62f,USEa6e58b8f
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,Postn-Cre; Nf2flox/flox,animal_models,Experimental Usage,PUB41444363,RESbcbdd0d7,USE97ef063a
PMID:41444363 | PMID:24817309,10.1038/s41598-025-32031-9 | 10.1371/journal.pone.0097320,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model. | Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,Nf2flox/flox,animal_models,Experimental Usage,PUBc6312b6b,RES173e403d,USE29a29aab
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,"Dhh::Cre, Nf1fl/fl, Pten",animal_models,Experimental Usage,PUB41036607,RES67640ce9,USEd16cef53
PMID:21216928 | PMID:26883872 | PMID:20551058,10.1158/1535-7163.MCT-10-0654 | 10.1016/j.jprot.2016.02.004 | 10.1158/0008-5472.CAN-09-3769,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes. | 3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Nf1 flox/flox; GFAP-Cre,animal_models,Experimental Usage,PUBff6e5d17,RESd6ee208c,USEeb7a22d4
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,DhhCre;Nf1fl/fl,animal_models,Experimental Usage,PUB28029918,RES41704967,USE263e15ab
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,Nf1Col1,animal_models,Experimental Usage,PUB24465906,RES3dbffed8,USEc3b6774a
PMID:28256556 | PMID:26904939,10.1038/srep43315 | 10.1016/j.celrep.2016.01.074,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,Nf1fl/fl;DhhCre,animal_models,Experimental Usage,PUB8758ff08,RES635e34f6,USE0a789228
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,Stat3(fl/fl);Nf1(fl/fl);DhhCre,animal_models,Experimental Usage,PUB26904939,RES1e67bb5c,USE7b2959a7
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,Nf1f/f;Trp53f/f;Nes-TK,animal_models,Experimental Usage,PUB34010628,RES92440303,USEff66b6af
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,Nf1f/f;Trp53f/f;CGD,animal_models,Experimental Usage,PUB34010628,RESe1def87b,USE05a596dd
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,Nf1/p53-/-,animal_models,Experimental Usage,PUB18242513,RESd995ff0b,USE3ec7523c
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,9a−/9a− Nf1,animal_models,Experimental Usage,PUB25917366,RES53af612e,USEc41d9803
PMID:17924978 | PMID:38945076,10.1111/j.1750-3639.2007.00105.x | 10.1016/j.redox.2024.103249,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations. | Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,Nf2 flox2/flox2,animal_models,Experimental Usage,PUBd4de1736,RESaff140e0,USEdc85bf39
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,Nf2 flox2/flox2 ;p16 Ink4a*/*,animal_models,Experimental Usage,PUB17924978,REScbe4b7bf,USE229824ed
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,H7;Nf1mut,animal_models,Experimental Usage,PUB37140985,RES51beed64,USE0da1cfca
PMID:24375753 | PMID:20551058 | PMID:28525381,10.1002/ana.24093 | 10.1158/0008-5472.CAN-09-3769 | 10.18632/oncotarget.17589,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. | The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/mut;GFAP-Cre,animal_models,Experimental Usage,PUB8087f428,RESb35d7371,USEb7686259
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,DhhCre,animal_models,Experimental Usage,PUB38127282,RES3195007c,USE868ec6be
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,Nf1flox/flox;Arf flox/flox;PostnCre+,animal_models,Experimental Usage,PUB38127282,RES167f736f,USEad75793d
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/wt,animal_models,Experimental Usage,PUB28525381,RES7a15e78d,USE1b40e576
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/mut,animal_models,Experimental Usage,PUB28525381,RESc3e4f29b,USEdfb9d814
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/flox; Olig2-Cre,animal_models,Experimental Usage,PUB28525381,RES027c26cd,USE444af014
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/mut; Olig2-Cre,animal_models,Experimental Usage,PUB28525381,RESdab9bd29,USEaddbdcb8
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/flox; Prom1-CreER,animal_models,Experimental Usage,PUB28525381,RES94bdb445,USEe96054b6
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/mut; Prom1-CreER,animal_models,Experimental Usage,PUB28525381,RESfdb125d4,USE12885d7e
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Periostin-CRE;NF2 fl/fl,animal_models,Experimental Usage,PUB36148553,RESa5ded38d,USE826fcb26
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Periostin-CRE;NF2 fl/fl YAP fl/fl,animal_models,Experimental Usage,PUB36148553,RESd7bf5ba5,USE6022176e
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Periostin-CRE;NF2 fl/fl TAZ fl/fl,animal_models,Experimental Usage,PUB36148553,RES59ac0b63,USE27d228d6
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,P0-CRE,animal_models,Experimental Usage,PUB36148553,RES6f70c029,USE6c016cdd
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,Postn-cre;Nf2f/f,animal_models,Experimental Usage,PUB32438526,RESe367efab,USEbc22d825
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,DhhCre;Nf1f/f;Luciferase,animal_models,Experimental Usage,PUB40723243,RES8b607c44,USE05a19618
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,Tg(U6x:nf2a/b-4sgRNA),animal_models,Development,PUB39415595,RESc67bdf21,USE11028e7a
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,NF1 R1947X minipig,animal_models,Development,PUB33978635,RES18e0d32c,USE6682d3f2
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,TetOff-Osx-/-Nf1,animal_models,Experimental Usage,PUB25043591,RESb3e83b3e,USEd96ff346
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,Osx-/-Nf1flox/flox,animal_models,Experimental Usage,PUB25043591,RES75e5cd5b,USEbfc8af71
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,"Osx-tTA,tetO-cre;Nf1flox/flox",animal_models,Experimental Usage,PUB25043591,RES0fabb727,USE7576fece
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,Nf2 mice,animal_models,Experimental Usage,PUB24371224,RES4be903d5,USEb3e58d4d
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,hGFAP-cre,animal_models,Experimental Usage,PUB25535838,RESedb243f5,USE642ea09d
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,Math1-cre,animal_models,Experimental Usage,PUB25535838,RESc5783883,USE34e227f7
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,L7-cre,animal_models,Experimental Usage,PUB25535838,RESc188abac,USEa1b13642
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,Nestin-creER,animal_models,Experimental Usage,PUB25535838,RES58594ca6,USE18334cd1
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,Nf1-Arf flox/flox ;Postn-Cre,animal_models,Experimental Usage,PUB33658640,RES70c2125d,USEd2b40d4b
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,tyrosine hydroxylase,antibodies,Experimental Usage,PUB31545171,RES977bc23d,USE48bfd89d
PMID:34415582 | PMID:41022755 | PMID:40590220 | PMID:31545171 | PMID:31015291 | PMID:32461556 | PMID:29715273 | PMID:36890585 | PMID:34257279,10.1002/glia.24075 | 10.1038/s41467-025-63619-4 | 10.1172/JCI188932 | 10.7554/eLife.48983 | 10.1126/scisignal.aau8749 | 10.1038/s41467-020-16432-0 | 10.1371/journal.pone.0196726 | 10.1186/s40478-023-01525-w | 10.1038/s41467-021-24505-x,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury. | Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1. | Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins. | Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,GFP,antibodies,Experimental Usage,PUBd1c63e84,RES553ef86e,USE67f538ce
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,TRIM23,antibodies,Experimental Usage,PUB32642734,RESa84b6af9,USE8c5ba4f9
PMID:32642734 | PMID:31462295 | PMID:39321200 | PMID:30479396 | PMID:38127282 | PMID:38216572 | PMID:37246765 | PMID:36598417,10.1093/noajnl/vdz026 | 10.1186/s40478-019-0792-5 | 10.1158/1078-0432.CCR-24-1454 | 10.1038/s41467-018-07452-y | 10.1158/1078-0432.CCR-23-2548 | 10.1038/s41467-024-44755-9 | 10.1093/neuonc/noad097 | 10.1158/2159-8290.CD-22-0786,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1. | Telomere alterations in neurofibromatosis type 1-associated solid tumors. | Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment. | NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. | Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,H3K27me3,antibodies,Experimental Usage,PUBa21950ae,RESbe629b01,USE8d353283
PMID:32642734 | PMID:32461556 | PMID:38502231 | PMID:24509877 | PMID:36322658 | PMID:34040258 | PMID:35511749 | PMID:26904939 | PMID:36241865 | PMID:24817309,10.1093/noajnl/vdz026 | 10.1038/s41467-020-16432-0 | 10.1172/JCI176748 | 10.1038/onc.2013.506 | 10.1126/sciadv.abo5442 | 10.1038/s41586-021-03580-6 | 10.1158/1535-7163.MCT-21-0947 | 10.1016/j.celrep.2016.01.074 | 10.1038/s12276-022-00850-9 | 10.1371/journal.pone.0097320,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1. | Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway. | Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,Cleaved-caspase 3,antibodies,Experimental Usage,PUB3159413e,RESa8a25947,USE8fc0aa89
PMID:40394150 | PMID:32699356 | PMID:32948135 | PMID:32642734 | PMID:35589737 | PMID:19191334 | PMID:32461556 | PMID:29715273 | PMID:34040258 | PMID:35945463 | PMID:29941005 | PMID:29438698 | PMID:24681606 | PMID:30055648 | PMID:33032988 | PMID:26904939 | PMID:40684195 | PMID:32642733 | PMID:36148553 | PMID:33356508 | PMID:37246765 | PMID:24371224 | PMID:25535838 | PMID:33591953 | PMID:38945076 | PMID:34930951 | PMID:39996452 | PMID:21216928,10.1038/s41416-025-03055-9 | 10.1038/s41467-020-17382-3 | 10.1186/s12885-020-07397-w | 10.1093/noajnl/vdz026 | 10.1038/s41467-022-30466-6 | 10.1002/glia.20845 | 10.1038/s41467-020-16432-0 | 10.1371/journal.pone.0196726 | 10.1038/s41586-021-03580-6 | 10.1007/s00401-022-02478-5 | 10.1186/s13023-018-0843-1 | 10.1016/j.ccell.2018.01.005 | 10.18632/oncotarget.1609 | 10.1186/s13104-018-3630-0 | 10.1158/0008-5472.CAN-20-1365 | 10.1016/j.celrep.2016.01.074 | 10.1186/s40478-025-02075-z | 10.1093/noajnl/vdz061 | 10.1093/brain/awac342 | 10.1177/0963689720964383 | 10.1093/neuonc/noad097 | 10.1158/0008-5472.CAN-13-2062 | 10.7554/eLife.05151 | 10.1172/jci.insight.146351 | 10.1016/j.redox.2024.103249 | 10.1038/s41536-021-00195-3 | 10.1111/cns.70287 | 10.1158/1535-7163.MCT-10-0654,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin. | Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1. | Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma. | C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. | Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. | Chromosome 8 gain is associated with high-grade transformation in MPNST. | Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy. | Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells. | Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,Ki67,antibodies,Experimental Usage,PUB0ac7f26e,RESd8b97e6d,USE848e8064
PMID:32699356 | PMID:18451155 | PMID:35589737 | PMID:19191334 | PMID:35945463 | PMID:20554030 | PMID:33356508 | PMID:25535838 | PMID:34930951 | PMID:25772366 | PMID:36241865 | PMID:20551058 | PMID:19144871,10.1038/s41467-020-17382-3 | 10.1158/0008-5472.CAN-07-6867 | 10.1038/s41467-022-30466-6 | 10.1002/glia.20845 | 10.1007/s00401-022-02478-5 | 10.1016/j.jneuroim.2010.05.002 | 10.1177/0963689720964383 | 10.7554/eLife.05151 | 10.1038/s41536-021-00195-3 | 10.1016/j.celrep.2015.02.041 | 10.1038/s12276-022-00850-9 | 10.1158/0008-5472.CAN-09-3769 | 10.3181/0809-RM-275,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Pten haploinsufficiency accelerates formation of high-grade astrocytomas. | Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. | Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,GFAP,antibodies,Experimental Usage,PUB0e22ebf2,RES0ee02cbb,USE9e707d10
PMID:36890585 | PMID:35589737 | PMID:38502231 | PMID:36322658 | PMID:34040258 | PMID:37990867 | PMID:20554030 | PMID:34930951 | PMID:20551058,10.1186/s40478-023-01525-w | 10.1038/s41467-022-30466-6 | 10.1172/JCI176748 | 10.1126/sciadv.abo5442 | 10.1038/s41586-021-03580-6 | 10.1242/dmm.049861 | 10.1016/j.jneuroim.2010.05.002 | 10.1038/s41536-021-00195-3 | 10.1158/0008-5472.CAN-09-3769,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Iba-1,antibodies,Experimental Usage,PUB4d0e29fc,RES71a06945,USE19d6f304
PMID:38907342 | PMID:37770931 | PMID:35589737 | PMID:35945463 | PMID:38216587 | PMID:29438698 | PMID:38744290 | PMID:38216572 | PMID:36598417 | PMID:39415595,10.1186/s40478-024-01821-z | 10.1186/s40478-023-01639-1 | 10.1038/s41467-022-30466-6 | 10.1007/s00401-022-02478-5 | 10.1038/s41467-023-40408-5 | 10.1016/j.ccell.2018.01.005 | 10.1016/j.crmeth.2024.100772 | 10.1038/s41467-024-44755-9 | 10.1158/2159-8290.CD-22-0786 | 10.1242/dmm.050862,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response. | Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas. | Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | Epigenetic reprogramming shapes the cellular landscape of schwannoma. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA. | Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.",,SOX10,antibodies,Experimental Usage,PUB492c7ca1,RES316770fb,USEed450684
PMID:35589737 | PMID:34930951,10.1038/s41467-022-30466-6 | 10.1038/s41536-021-00195-3,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,Rbpms,antibodies,Experimental Usage,PUBd14bee11,RES1139657c,USE3ed6dff1
PMID:35589737 | PMID:23328114 | PMID:25772366,10.1038/s41467-022-30466-6 | 10.18632/oncotarget.793 | 10.1016/j.celrep.2015.02.041,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,Tuj-1,antibodies,Experimental Usage,PUBa33a4fb8,RESb416ca18,USEf4964afe
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,Peripherin,antibodies,Experimental Usage,PUB35589737,RES44665631,USE730961f7
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,ISL1,antibodies,Experimental Usage,PUB35589737,RESe19b2765,USEcc486eac
PMID:28465357 | PMID:29438698,10.1101/gad.298703.117 | 10.1016/j.ccell.2018.01.005,Identification of hair shaft progenitors that create a niche for hair pigmentation. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,Krox20,antibodies,Experimental Usage,PUB52d550cc,RES60a165be,USE1cedac3b
PMID:38216123 | PMID:38481529 | PMID:37446790 | PMID:39890807 | PMID:29438698 | PMID:29847659 | PMID:36241865,10.1016/j.molmet.2024.101876 | 10.3389/fcell.2024.1359561 | 10.3390/molecules28135128 | 10.1038/s41598-024-84493-y | 10.1016/j.ccell.2018.01.005 | 10.1167/iovs.17-22588 | 10.1038/s12276-022-00850-9,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer. | Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1. | Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway. | Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,neurofibromin,antibodies,Experimental Usage,PUB25df4dd2,RESb9e87b61,USE0373599f
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,pERα S118,antibodies,Experimental Usage,PUB38216123,RESbbf9198e,USEf7425a5c
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,pERK T202/Y204,antibodies,Experimental Usage,PUB38216123,RES28c68bc2,USEe527e860
PMID:38216123 | PMID:24681606,10.1016/j.molmet.2024.101876 | 10.18632/oncotarget.1609,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,pAKT S473,antibodies,Experimental Usage,PUB7a9a8ba1,RES24b15955,USEa553be6a
PMID:33078583 | PMID:38216123 | PMID:39129390 | PMID:34257279 | PMID:18367665,10.1002/jcsm.12632 | 10.1016/j.molmet.2024.101876 | 10.1002/1878-0261.13704 | 10.1038/s41467-021-24505-x | 10.1124/jpet.107.135830,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis. | NF1 deficiency drives metabolic reprogramming in ER+ breast cancer. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila. | Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,β-tubulin,antibodies,Experimental Usage,PUB0bfb229f,RESebf12b3d,USE048715d2
PMID:34040258 | PMID:34930951,10.1038/s41586-021-03580-6 | 10.1038/s41536-021-00195-3,NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,BRN3A,antibodies,Experimental Usage,PUBa477c5c8,RESb43ac02e,USE83bf1b1c
PMID:34930951 | PMID:23328114,10.1038/s41536-021-00195-3 | 10.18632/oncotarget.793,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy. | Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,Caspase9,antibodies,Experimental Usage,PUB3f1ae47b,RES069d5316,USE6041e891
PMID:36890585 | PMID:25535838 | PMID:34930951 | PMID:36241865,10.1186/s40478-023-01525-w | 10.7554/eLife.05151 | 10.1038/s41536-021-00195-3 | 10.1038/s12276-022-00850-9,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,NeuN,antibodies,Experimental Usage,PUB2c983076,RES2dfaf2de,USE862de29e
PMID:40217315 | PMID:30479396 | PMID:29941005 | PMID:34010628 | PMID:40684195 | PMID:33356508 | PMID:34930951,10.1186/s13073-025-01462-4 | 10.1038/s41467-018-07452-y | 10.1186/s13023-018-0843-1 | 10.1016/j.stem.2021.04.029 | 10.1186/s40478-025-02075-z | 10.1177/0963689720964383 | 10.1038/s41536-021-00195-3,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations. | NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study. | Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,CD45,antibodies,Experimental Usage,PUBd687db66,RES01c548c8,USEb30fe317
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,HLA-DR,antibodies,Experimental Usage,PUB41149489,RES095b87c3,USE096bea64
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,CD33,antibodies,Experimental Usage,PUB41149489,RES03b634a1,USE715d5c38
PMID:30542164 | PMID:38907342 | PMID:41149489 | PMID:36890585 | PMID:28256556,10.1038/s41586-018-0774-y | 10.1186/s40478-024-01821-z | 10.3390/curroncol32100569 | 10.1186/s40478-023-01525-w | 10.1038/srep43315,"Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. | snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response. | Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90. | Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.",,CD11b,antibodies,Experimental Usage,PUBcf3c7461,RES6dbc6eca,USE45d0939e
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,CD9,antibodies,Experimental Usage,PUB41149489,RESb05a75f6,USEced50f34
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,CD81,antibodies,Experimental Usage,PUB41149489,RES8665ff08,USE91035ca4
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,TOMM20,antibodies,Experimental Usage,PUB41149489,RES30e78193,USEc2125fcf
PMID:41149489 | PMID:27956228,10.3390/curroncol32100569 | 10.1053/j.gastro.2016.12.002,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90. | Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,HSP90,antibodies,Experimental Usage,PUB700591a3,RES71568c97,USEa54f1ace
PMID:36730269 | PMID:41149489 | PMID:33273014 | PMID:29847659 | PMID:20554030 | PMID:26219339 | PMID:21072183 | PMID:18483311 | PMID:38216572 | PMID:24371224 | PMID:32419643,10.1371/journal.pone.0277305 | 10.3390/curroncol32100569 | 10.1074/jbc.RA120.014960 | 10.1167/iovs.17-22588 | 10.1016/j.jneuroim.2010.05.002 | 10.18632/oncotarget.4858 | 10.1371/journal.pone.0013791 | 10.1158/1535-7163.MCT-07-2335 | 10.1038/s41467-024-44755-9 | 10.1158/0008-5472.CAN-13-2062 | 10.1177/1533033820919759,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90. | mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. | Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,AKT,antibodies,Experimental Usage,PUBcf0c044d,RES5744e760,USE6b8f7d78
PMID:33442015 | PMID:36730269 | PMID:41149489 | PMID:38216572 | PMID:24371224 | PMID:32419643,10.1038/s41591-020-01193-6 | 10.1371/journal.pone.0277305 | 10.3390/curroncol32100569 | 10.1038/s41467-024-44755-9 | 10.1158/0008-5472.CAN-13-2062 | 10.1177/1533033820919759,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. | Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,pAKT,antibodies,Experimental Usage,PUB94f66c42,RES58812f68,USEbcd0f8aa
PMID:36730269 | PMID:41564118 | PMID:41149489 | PMID:39129390 | PMID:29847659 | PMID:34257279 | PMID:38714355 | PMID:38216572 | PMID:18413802,10.1371/journal.pone.0277305 | 10.1371/journal.pone.0340183 | 10.3390/curroncol32100569 | 10.1002/1878-0261.13704 | 10.1167/iovs.17-22588 | 10.1038/s41467-021-24505-x | 10.1158/1535-7163.MCT-23-0510 | 10.1038/s41467-024-44755-9 | 10.1158/1535-7163.MCT-07-0518,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,ERK,antibodies,Experimental Usage,PUB32cbb88c,RES3451c7e1,USE63cf4e76
PMID:32699356 | PMID:36730269 | PMID:41564118 | PMID:41149489 | PMID:27956228 | PMID:24509877 | PMID:24681606 | PMID:28166733 | PMID:40684195 | PMID:38216572 | PMID:37246765 | PMID:24371224 | PMID:25535838,10.1038/s41467-020-17382-3 | 10.1371/journal.pone.0277305 | 10.1371/journal.pone.0340183 | 10.3390/curroncol32100569 | 10.1053/j.gastro.2016.12.002 | 10.1038/onc.2013.506 | 10.18632/oncotarget.1609 | 10.1186/s12864-017-3519-7 | 10.1186/s40478-025-02075-z | 10.1038/s41467-024-44755-9 | 10.1093/neuonc/noad097 | 10.1158/0008-5472.CAN-13-2062 | 10.7554/eLife.05151,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90. | Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,p-Erk,antibodies,Experimental Usage,PUBe301120b,RES5412d45a,USE93f4fc34
PMID:41022755 | PMID:40590220 | PMID:21072183 | PMID:29670214 | PMID:37681415 | PMID:25043591 | PMID:20200958 | PMID:24375753,10.1038/s41467-025-63619-4 | 10.1172/JCI188932 | 10.1371/journal.pone.0013791 | 10.1038/s41598-018-24310-5 | 10.1172/jci.insight.168445 | 10.1002/jbmr.2316 | 10.1002/jbmr.42 | 10.1002/ana.24093,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Restoring functional neurofibromin by protein transduction. | Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation. | Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice. | Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts. | Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,ERK1/2,antibodies,Experimental Usage,PUB5b19634c,RES565306bf,USE0bc3c6de
PMID:41022755 | PMID:24932921 | PMID:33436083 | PMID:33934112 | PMID:29670214 | PMID:25043591 | PMID:20200958,10.1038/s41467-025-63619-4 | 10.1002/jbmr.2298 | 10.1186/s13072-020-00380-6 | 10.1038/s41419-021-03716-6 | 10.1038/s41598-018-24310-5 | 10.1002/jbmr.2316 | 10.1002/jbmr.42,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1. | Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | Restoring functional neurofibromin by protein transduction. | Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice. | Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,phospho-ERK1/2,antibodies,Experimental Usage,PUB08df3115,RESa9627f3f,USE7e4d9a78
PMID:40590220 | PMID:36420221 | PMID:31836666 | PMID:24595234 | PMID:36689660 | PMID:40225167 | PMID:16835260,10.1172/JCI188932 | 10.1016/j.omtn.2022.10.026 | 10.1074/jbc.RA119.010934 | 10.1371/journal.pone.0090853 | 10.1073/pnas.2208960120 | 10.1155/2023/9628049 | 10.1093/hmg/ddl165,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype | Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization. | Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome. | Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,Flag,antibodies,Experimental Usage,PUBa679b0aa,RESe48dbe33,USEd751484a
PMID:31836666 | PMID:40225167,10.1074/jbc.RA119.010934 | 10.1155/2023/9628049,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,V5,antibodies,Experimental Usage,PUB4a06cb6d,RES36bf1087,USEd4078ed7
PMID:41022755 | PMID:31836666 | PMID:40225167 | PMID:36689660,10.1038/s41467-025-63619-4 | 10.1074/jbc.RA119.010934 | 10.1155/2023/9628049 | 10.1073/pnas.2208960120,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,HA,antibodies,Experimental Usage,PUBcf655c0a,RES19834e41,USE6638d857
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,pEGFR,antibodies,Experimental Usage,PUB31836666,RES8bdcfcad,USEd66063a3
PMID:31836666 | PMID:37681415 | PMID:36689660,10.1074/jbc.RA119.010934 | 10.1172/jci.insight.168445 | 10.1073/pnas.2208960120,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,KRAS,antibodies,Experimental Usage,PUB400cdf5f,RES72e152bc,USE8524191a
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,collagen IV,antibodies,Experimental Usage,PUB33078583,RES310b4df9,USE40c4e4f1
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,MyHC type 1,antibodies,Experimental Usage,PUB33078583,RESb34814f9,USEa12f3cfd
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,MyHC type 2A,antibodies,Experimental Usage,PUB33078583,RESf87e4d96,USE47421a74
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,laminin,antibodies,Experimental Usage,PUB33078583,RES2fd9e071,USE2194e983
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,Pax7,antibodies,Experimental Usage,PUB33078583,RES3dc39ca7,USEd75f1a6f
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,myosin heavy chain,antibodies,Experimental Usage,PUB33078583,RES17d79fda,USEc1b95c9d
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,beta III tubulin,antibodies,Experimental Usage,PUB33078583,RESf7ca7eb9,USE0644fceb
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,perilipin A/B,antibodies,Experimental Usage,PUB33078583,RES9e064d1f,USEb141d634
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,PPARG,antibodies,Experimental Usage,PUB33078583,RES75dca126,USEe827cbb0
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,phosphor (pThr172) AMPKa,antibodies,Experimental Usage,PUB33078583,RES0353103f,USE285046f8
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,AMPKα,antibodies,Experimental Usage,PUB33078583,RES7dd46be6,USE2935b7c5
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,phosphor (s235/236) S6,antibodies,Experimental Usage,PUB33078583,RESc52ba0e3,USE47ef8a97
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,MyHC type 2B,antibodies,Experimental Usage,PUB33078583,RESb2f1f8e4,USEd73cfb0f
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,phosphor (Ser473) AKT,antibodies,Experimental Usage,PUB33078583,RESe49cf5ce,USE6204e603
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,phospho (Ser1101) IRS-1,antibodies,Experimental Usage,PUB33078583,RES5028922e,USEba124166
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,phospho (Ser636/639) IRS-1,antibodies,Experimental Usage,PUB33078583,RES873843cc,USEa02d84ad
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,DIG-Fab,antibodies,Experimental Usage,PUB33078583,RES57dcbaf6,USEf2d2d684
PMID:38201517 | PMID:18367665 | PMID:18413802 | PMID:36689660,10.3390/cancers16010089 | 10.1124/jpet.107.135830 | 10.1158/1535-7163.MCT-07-0518 | 10.1073/pnas.2208960120,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,RAS,antibodies,Experimental Usage,PUBaffcbb27,RES2f7b6ece,USE8d937a24
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,N-RAS,antibodies,Experimental Usage,PUB38201517,RES648182ec,USE3f711f07
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,RAB5A,antibodies,Experimental Usage,PUB38201517,RES1ed3349d,USEe3a87c8b
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,RAP1A,antibodies,Experimental Usage,PUB38201517,RES5cd338c4,USE48d3a803
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,MYF-4,antibodies,Experimental Usage,PUB36598417,RESda1da332,USE2fb3c306
PMID:24040940 | PMID:25851896 | PMID:30479396 | PMID:24681606 | PMID:40025578 | PMID:30055648 | PMID:18636037 | PMID:38744290 | PMID:36148553 | PMID:33356508 | PMID:41001593 | PMID:33591953 | PMID:36598417 | PMID:21111000 | PMID:33767727 | PMID:15255999 | PMID:15240917 | PMID:19144871,10.1186/1479-5876-11-213 | 10.3988/jcn.2015.11.2.172 | 10.1038/s41467-018-07452-y | 10.18632/oncotarget.1609 | 10.1186/s40478-025-01965-6 | 10.1186/s13104-018-3630-0 | 10.1097/MAO.0b013e31817f7398 | 10.1016/j.crmeth.2024.100772 | 10.1093/brain/awac342 | 10.1177/0963689720964383 | 10.1080/23723556.2025.2561292 | 10.1172/jci.insight.146351 | 10.1158/2159-8290.CD-22-0786 | 10.1016/j.jneumeth.2010.10.021 | 10.3389/fgene.2021.603195 | 10.1186/1476-4598-3-20 | 10.1155/S1110724304308107 | 10.3181/0809-RM-275,"Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors. | Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures. | NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study. | A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma. | C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. | Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor. | Chromosome 8 gain is associated with high-grade transformation in MPNST. | Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA. | A novel imaging-compatible sciatic nerve schwannoma model. | Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing. | Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR. | Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone. | Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.",,S100,antibodies,Experimental Usage,PUB0e209f5a,RESc503fac4,USE65c84d59
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,HMB45,antibodies,Experimental Usage,PUB36598417,RES4292006c,USE65456cee
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,Melan-A,antibodies,Experimental Usage,PUB36598417,RESfca4c6a6,USEb7c9341a
PMID:29941005 | PMID:25851896,10.1186/s13023-018-0843-1 | 10.3988/jcn.2015.11.2.172,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study. | Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,CD90,antibodies,Experimental Usage,PUBf9d77c57,RES2b594c34,USE041bd668
PMID:41022755 | PMID:38175707 | PMID:41444363 | PMID:38216572 | PMID:37246765 | PMID:39110684 | PMID:34646065,10.1038/s41467-025-63619-4 | 10.1172/jci.insight.168826 | 10.1038/s41598-025-32031-9 | 10.1038/s41467-024-44755-9 | 10.1093/neuonc/noad097 | 10.1371/journal.pone.0308207 | 10.1155/2021/9386823,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas. | Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. | Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers. | Survival and,,S100B,antibodies,Experimental Usage,PUBee6b9660,RESbec1e8c1,USE2fab2af7
PMID:27956228 | PMID:24371224,10.1053/j.gastro.2016.12.002 | 10.1158/0008-5472.CAN-13-2062,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,beta-Catenin,antibodies,Experimental Usage,PUB81eacaf8,RESa1793d36,USEb1222fe3
PMID:27956228 | PMID:24509877 | PMID:20049725 | PMID:32396062,10.1053/j.gastro.2016.12.002 | 10.1038/onc.2013.506 | 10.1002/emmm.200900027 | 10.7554/eLife.55137,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,SOX9,antibodies,Experimental Usage,PUB2f78033e,RESd8bc51ac,USEd559159f
PMID:32457840 | PMID:20195187 | PMID:21072183 | PMID:31015291 | PMID:28126595 | PMID:29715273 | PMID:30274821 | PMID:39415595 | PMID:38945076 | PMID:24595234,10.3389/fonc.2020.00687 | 10.1097/MAO.0b013e3181d2777f | 10.1371/journal.pone.0013791 | 10.1126/scisignal.aau8749 | 10.1016/j.ebiom.2017.01.020 | 10.1371/journal.pone.0196726 | 10.1016/j.ebiom.2018.09.042 | 10.1242/dmm.050862 | 10.1016/j.redox.2024.103249 | 10.1371/journal.pone.0090853,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling. | Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. | p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins. | Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target. | Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b. | Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation. | In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.",,Merlin,antibodies,Experimental Usage,PUB935bfae1,RES1e67e0f9,USE1ecb3ade
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,collagen XV,antibodies,Experimental Usage,PUB40394150,RES20db9b9e,USE1fda37a0
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,collagen XVIII,antibodies,Experimental Usage,PUB40394150,RES9ab8a99c,USE17b854af
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,K1,antibodies,Experimental Usage,PUB30479396,REScc2fc8a5,USE86d3271a
PMID:41022755 | PMID:28166733 | PMID:38714355 | PMID:39472976 | PMID:41564118 | PMID:30479396 | PMID:39129390 | PMID:34257279 | PMID:34011935 | PMID:25535838,10.1038/s41467-025-63619-4 | 10.1186/s12864-017-3519-7 | 10.1158/1535-7163.MCT-23-0510 | 10.1186/s40478-024-01875-z | 10.1371/journal.pone.0340183 | 10.1038/s41467-018-07452-y | 10.1002/1878-0261.13704 | 10.1038/s41467-021-24505-x | 10.1038/s41419-021-03802-9 | 10.7554/eLife.05151,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma. | NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes. | Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,NF1,antibodies,Experimental Usage,PUB34bef85d,RESfb1ea3d8,USE5a374805
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,LUMICAN,antibodies,Experimental Usage,PUB30479396,RES14393003,USE1efe9fef
PMID:30542164 | PMID:30479396 | PMID:38502231 | PMID:30531922 | PMID:36322658 | PMID:38216587 | PMID:39321200 | PMID:37410426,10.1038/s41586-018-0774-y | 10.1038/s41467-018-07452-y | 10.1172/JCI176748 | 10.1038/s41591-018-0263-8 | 10.1126/sciadv.abo5442 | 10.1038/s41467-023-40408-5 | 10.1158/1078-0432.CCR-24-1454 | 10.1158/1078-0432.CCR-23-0749,"Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. | NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | The molecular landscape of glioma in patients with Neurofibromatosis 1. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Epigenetic reprogramming shapes the cellular landscape of schwannoma. | Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,CD3,antibodies,Experimental Usage,PUBaf6a303f,RES2794eb0e,USE47b9a6eb
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,CD28,antibodies,Experimental Usage,PUB30479396,RESd23ff8ae,USE1a06cc8a
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,CD69,antibodies,Experimental Usage,PUB30479396,RES51e8dd77,USEad842fb0
PMID:30479396 | PMID:38502231 | PMID:40025578,10.1038/s41467-018-07452-y | 10.1172/JCI176748 | 10.1186/s40478-025-01965-6,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,CD4,antibodies,Experimental Usage,PUB48f1d791,RESdf5c02a6,USE8387e0a6
PMID:30479396 | PMID:30531922 | PMID:34040258 | PMID:39321200,10.1038/s41467-018-07452-y | 10.1038/s41591-018-0263-8 | 10.1038/s41586-021-03580-6 | 10.1158/1078-0432.CCR-24-1454,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | The molecular landscape of glioma in patients with Neurofibromatosis 1. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,CD8,antibodies,Experimental Usage,PUBdf58719e,RES5d1e1fdd,USE76f6fec6
PMID:30479396 | PMID:38502231 | PMID:33356508 | PMID:39321200,10.1038/s41467-018-07452-y | 10.1172/JCI176748 | 10.1177/0963689720964383 | 10.1158/1078-0432.CCR-24-1454,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. | Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,FoxP3,antibodies,Experimental Usage,PUBb8ef01a7,RES89deace3,USEbd48c03d
PMID:30479396 | PMID:37410426,10.1038/s41467-018-07452-y | 10.1158/1078-0432.CCR-23-0749,"NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,B220,antibodies,Experimental Usage,PUB5cce632b,RES866103ab,USE706d5377
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,MIA,antibodies,Experimental Usage,PUB21726432,RESee281484,USE950c7c5f
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,AQP4,antibodies,Experimental Usage,PUB19191334,RES3208dd65,USE09bb1415
PMID:36730269 | PMID:19191334,10.1371/journal.pone.0277305 | 10.1002/glia.20845,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,NG2,antibodies,Experimental Usage,PUB33e6ac48,RESe8113661,USE722618a9
PMID:19191334 | PMID:25772366,10.1002/glia.20845 | 10.1016/j.celrep.2015.02.041,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,O4,antibodies,Experimental Usage,PUB02d15a58,RES4ac7492c,USE752d1934
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,LHX2,antibodies,Experimental Usage,PUB19191334,RESa4ce3604,USE5aab391d
PMID:19191334 | PMID:37164978,10.1002/glia.20845 | 10.1038/s41467-023-38432-6,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,APC,antibodies,Experimental Usage,PUB573c3f1b,RES2125c45c,USEd228408d
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,FOXG1,antibodies,Experimental Usage,PUB19191334,RES7454f212,USE9936add4
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,FOXP2,antibodies,Experimental Usage,PUB19191334,RES7deb2105,USE9a545877
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,HOXB3,antibodies,Experimental Usage,PUB19191334,RES669aaae4,USEebd3e9a5
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,GLAST,antibodies,Experimental Usage,PUB19191334,RESbcedbce8,USEfc01ac0e
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,NF1GRP-D,antibodies,Experimental Usage,PUB19191334,REScb3fd620,USE44867ab4
PMID:31015291 | PMID:40684195,10.1126/scisignal.aau8749 | 10.1186/s40478-025-02075-z,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,RFP,antibodies,Experimental Usage,PUB8ead058e,RESc17981bf,USE3db7ba14
PMID:36730269 | PMID:40225167,10.1371/journal.pone.0277305 | 10.1155/2023/9628049,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,MYC,antibodies,Experimental Usage,PUBd1af51ae,RES9b798b26,USE01d1515b
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,phosphorylated ERK Thr202/Tyr204,antibodies,Experimental Usage,PUB21199799,RES1b4beed1,USE31e4ab38
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,phosphorylated Akt Ser473,antibodies,Experimental Usage,PUB21199799,RES12436fb2,USEa7f19546
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,phosphorylated S6 Ser235/236,antibodies,Experimental Usage,PUB21199799,RESe01881f3,USE947425dd
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,γH2AX Ser139,antibodies,Experimental Usage,PUB21199799,RES350c84ec,USEf4f3a72d
PMID:33934112 | PMID:35393510 | PMID:33658640 | PMID:24824755,10.1038/s41419-021-03716-6 | 10.1038/s41418-022-00991-4 | 10.1038/s41416-021-01270-8 | 10.1371/journal.pone.0096733,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,HIF1α,antibodies,Experimental Usage,PUB5194fc6f,RES5bbea64f,USEdadefa09
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,BNIP3,antibodies,Experimental Usage,PUB24824755,RES9f563b7c,USE7ea128ab
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,BECLIN1,antibodies,Experimental Usage,PUB24824755,RES002e9f1b,USE25e27d28
PMID:38203448 | PMID:24824755,10.3390/ijms25010277 | 10.1371/journal.pone.0096733,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,LC3,antibodies,Experimental Usage,PUB00a07f82,RESd52b7a0b,USE3e757393
PMID:32699356 | PMID:32948135 | PMID:32461556 | PMID:35945463 | PMID:30274821 | PMID:30055648 | PMID:24371224,10.1038/s41467-020-17382-3 | 10.1186/s12885-020-07397-w | 10.1038/s41467-020-16432-0 | 10.1007/s00401-022-02478-5 | 10.1016/j.ebiom.2018.09.042 | 10.1186/s13104-018-3630-0 | 10.1158/0008-5472.CAN-13-2062,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,p53,antibodies,Experimental Usage,PUB5b96fab6,RES808898e8,USEb1f4473d
PMID:32699356 | PMID:18451155 | PMID:29715273 | PMID:35945463 | PMID:20554030 | PMID:20551058,10.1038/s41467-020-17382-3 | 10.1158/0008-5472.CAN-07-6867 | 10.1371/journal.pone.0196726 | 10.1007/s00401-022-02478-5 | 10.1016/j.jneuroim.2010.05.002 | 10.1158/0008-5472.CAN-09-3769,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Pten haploinsufficiency accelerates formation of high-grade astrocytomas. | Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Olig2,antibodies,Experimental Usage,PUBd9377bb9,RES4203d97c,USE50d497d7
PMID:32699356 | PMID:24509877 | PMID:25535838,10.1038/s41467-020-17382-3 | 10.1038/onc.2013.506 | 10.7554/eLife.05151,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,p-S6,antibodies,Experimental Usage,PUB0c8cd157,RESf3e1fc12,USEe4239c53
PMID:32699356 | PMID:36322658 | PMID:29438698 | PMID:18636037 | PMID:18242513 | PMID:32396062 | PMID:25535838,10.1038/s41467-020-17382-3 | 10.1126/sciadv.abo5442 | 10.1016/j.ccell.2018.01.005 | 10.1097/MAO.0b013e31817f7398 | 10.1016/j.ccr.2008.01.003 | 10.7554/eLife.55137 | 10.7554/eLife.05151,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study. | The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. | Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,BrdU,antibodies,Experimental Usage,PUB3e363a1f,RES7b76f73a,USE32588739
PMID:32461556 | PMID:24371224,10.1038/s41467-020-16432-0 | 10.1158/0008-5472.CAN-13-2062,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,Cytokeratin-8,antibodies,Experimental Usage,PUBa6a0fb17,RES8bd728a8,USE0c353bb7
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,ABCC1,antibodies,Experimental Usage,PUB24040940,RESefb2d651,USE48b2df20
PMID:34415582 | PMID:20551058,10.1002/glia.24075 | 10.1158/0008-5472.CAN-09-3769,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,mCherry,antibodies,Experimental Usage,PUB1905a64c,RES9f40530c,USEeccc046e
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,NHE1,antibodies,Experimental Usage,PUB32457840,RESf7a0766f,USE8aee8dba
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,ERBB3 Y1197,antibodies,Experimental Usage,PUB33273014,RES65b70597,USE1910622b
PMID:33273014 | PMID:20195187,10.1074/jbc.RA120.014960 | 10.1097/MAO.0b013e3181d2777f,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,ERBB3,antibodies,Experimental Usage,PUBa2978151,RES99cc5902,USE3c4221c9
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,EPHA2 S897,antibodies,Experimental Usage,PUB33273014,RES1a13d307,USE95b14502
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,NDRG1 T346,antibodies,Experimental Usage,PUB33273014,RESf5cc1980,USE3b7763e9
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,Akt S473,antibodies,Experimental Usage,PUB33273014,RES036b393f,USE1a900f15
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,Akt T308,antibodies,Experimental Usage,PUB33273014,RES326aa6fc,USE8c3a6525
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,p70S6K T389,antibodies,Experimental Usage,PUB33273014,RESb7c2c29b,USEbe6efc45
PMID:33273014 | PMID:26219339,10.1074/jbc.RA120.014960 | 10.18632/oncotarget.4858,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,p70S6K,antibodies,Experimental Usage,PUB828d09ce,RES4cdcb770,USE5722a739
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,ribosomal S6 S240/244,antibodies,Experimental Usage,PUB33273014,RES9dec6af5,USEecdef440
PMID:33273014 | PMID:26219339,10.1074/jbc.RA120.014960 | 10.18632/oncotarget.4858,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,S6,antibodies,Experimental Usage,PUB828d09ce,RESf589cffe,USE579a5bae
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,IGF1R Y1135/36/IR Y1150/51,antibodies,Experimental Usage,PUB33273014,RESfd49bc06,USE92c65fbe
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,IGF1R,antibodies,Experimental Usage,PUB33273014,RES10cd711a,USE8fd16474
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,FOXO1/3a T24/T32,antibodies,Experimental Usage,PUB33273014,RESac092c27,USE58c0711a
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,FOXO3,antibodies,Experimental Usage,PUB33273014,RES1f2f41fa,USE788c82af
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,EPHA2,antibodies,Experimental Usage,PUB33273014,RES724ed0f5,USEb2491c3e
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,secreted form of NRG1,antibodies,Experimental Usage,PUB33273014,RES29bc5b6e,USE012ceda6
PMID:33273014 | PMID:26219339,10.1074/jbc.RA120.014960 | 10.18632/oncotarget.4858,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,NDRG1,antibodies,Experimental Usage,PUB828d09ce,RES5a12f51e,USEd8ad6c86
PMID:33273014 | PMID:38216572 | PMID:19144871,10.1074/jbc.RA120.014960 | 10.1038/s41467-024-44755-9 | 10.3181/0809-RM-275,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,NF2/merlin,antibodies,Experimental Usage,PUB16e2956c,RES2fa09c89,USE2b98597a
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,STING,antibodies,Experimental Usage,PUB38502231,RESc8269a94,USE5250f03f
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,TBK1,antibodies,Experimental Usage,PUB38502231,RESd5be907f,USE467e9c06
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,p-TBK1,antibodies,Experimental Usage,PUB38502231,RES8de9f9fb,USE2e59f3f0
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,IRF3,antibodies,Experimental Usage,PUB38502231,RESf9c1c332,USE11a4491b
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,p-IRF3,antibodies,Experimental Usage,PUB38502231,RES299f779f,USE8b7b539a
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,NF-κB,antibodies,Experimental Usage,PUB38502231,RESffadc3d9,USE63ad7fca
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,p-NF-κB,antibodies,Experimental Usage,PUB38502231,RESaa2815e2,USE233d87e0
PMID:38502231 | PMID:40025578 | PMID:39321200 | PMID:37410426,10.1172/JCI176748 | 10.1186/s40478-025-01965-6 | 10.1158/1078-0432.CCR-24-1454 | 10.1158/1078-0432.CCR-23-0749,"STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment. | Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,PD-L1,antibodies,Experimental Usage,PUB0422ea99,RES8766a5dd,USE426919aa
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,CTLA-4,antibodies,Experimental Usage,PUB38502231,RES9a7c4290,USE4d7e3bcd
PMID:38502231 | PMID:30531922,10.1172/JCI176748 | 10.1038/s41591-018-0263-8,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | The molecular landscape of glioma in patients with Neurofibromatosis 1.,,CD20,antibodies,Experimental Usage,PUB07ef860a,RES880eade8,USEc59066ae
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,CD8α,antibodies,Experimental Usage,PUB38502231,RES103c9f1e,USE5ca1f440
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,iNOS,antibodies,Experimental Usage,PUB38502231,RESe7d7d1a3,USE8a0d3faf
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,mannose receptor,antibodies,Experimental Usage,PUB38502231,RES54626432,USE3e2271af
PMID:38502231 | PMID:39415595,10.1172/JCI176748 | 10.1242/dmm.050862,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,p-H3,antibodies,Experimental Usage,PUB57863e2b,RESf3880df6,USEca6e6a69
PMID:38502231 | PMID:38714355 | PMID:33658640,10.1172/JCI176748 | 10.1158/1535-7163.MCT-23-0510 | 10.1038/s41416-021-01270-8,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,cleaved PARP,antibodies,Experimental Usage,PUB37c470a7,RES2f29c25d,USE6b328544
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,PD-1,antibodies,Experimental Usage,PUB38502231,RES2a1894ee,USE6673af51
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,βIII-tubulin,antibodies,Experimental Usage,PUB41022755,RES44d6247d,USE6bc37ce7
PMID:41022755 | PMID:38744290,10.1038/s41467-025-63619-4 | 10.1016/j.crmeth.2024.100772,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,NGFR,antibodies,Experimental Usage,PUB93b48df0,RES4c0d6c66,USE4645f122
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,Human Nuclear Antigen,antibodies,Experimental Usage,PUB41022755,RES2987939f,USE98d6dd95
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,Drosophila neurofibromin,antibodies,Experimental Usage,PUB39129390,RESe7ee1579,USE47d941ac
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,human neurofibromin,antibodies,Experimental Usage,PUB39129390,RESb1341551,USEc4962954
PMID:39129390 | PMID:29847659 | PMID:34257279 | PMID:34011935 | PMID:38714355 | PMID:39472976 | PMID:18413802,10.1002/1878-0261.13704 | 10.1167/iovs.17-22588 | 10.1038/s41467-021-24505-x | 10.1038/s41419-021-03802-9 | 10.1158/1535-7163.MCT-23-0510 | 10.1186/s40478-024-01875-z | 10.1158/1535-7163.MCT-07-0518,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma. | NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,phospho-ERK,antibodies,Experimental Usage,PUBcaae9b8d,RESf3e2fe87,USEf2da0233
PMID:39129390 | PMID:33658640 | PMID:25043298,10.1002/1878-0261.13704 | 10.1038/s41416-021-01270-8 | 10.1038/onc.2014.185,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | Oncogenic role of Merlin/NF2 in glioblastoma.,,PARP,antibodies,Experimental Usage,PUBba207846,RESef0ab296,USEe2083f5a
PMID:39129390 | PMID:38203448,10.1002/1878-0261.13704 | 10.3390/ijms25010277,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,LC3B,antibodies,Experimental Usage,PUBfb37c3d0,RESfcddb89f,USE16f4f480
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,p44/42 MAPK (ERK1/2),antibodies,Experimental Usage,PUB30571760,RES6049cff2,USE9ed64b29
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2),antibodies,Experimental Usage,PUB30571760,RES352a6d85,USE437a98c0
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,phosphatidylinositol 3-kinase (PI3K),antibodies,Experimental Usage,PUB30571760,RES91dd6f1f,USE2454efd5
PMID:31462295 | PMID:30531922 | PMID:35945463,10.1186/s40478-019-0792-5 | 10.1038/s41591-018-0263-8 | 10.1007/s00401-022-02478-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors. | The molecular landscape of glioma in patients with Neurofibromatosis 1. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,ATRX,antibodies,Experimental Usage,PUBfe83e3d6,RES443bd5df,USE041589ac
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,GZMB,antibodies,Experimental Usage,PUB30531922,RESa542f83b,USEff1cd348
PMID:30531922 | PMID:38216587,10.1038/s41591-018-0263-8 | 10.1038/s41467-023-40408-5,The molecular landscape of glioma in patients with Neurofibromatosis 1. | Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,CD68,antibodies,Experimental Usage,PUB69caabd0,RES6625c961,USE56fd8b8c
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,"indoleamine 2,3-dioxygenase",antibodies,Experimental Usage,PUB38931352,RES448c30f3,USE868b328d
PMID:38931352 | PMID:34011935,10.3390/ph17060685 | 10.1038/s41419-021-03802-9,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,AHR,antibodies,Experimental Usage,PUB585ffa58,RES5632cba7,USE4130a500
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,TDO2,antibodies,Experimental Usage,PUB38931352,RES0e47d126,USEbdf2d782
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,phospho-Merlin,antibodies,Experimental Usage,PUB28126595,RES870ee31a,USE2cfda85f
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,HDAC1,antibodies,Experimental Usage,PUB28126595,RES0ce86ab6,USE467e24ef
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,PDLIM2,antibodies,Experimental Usage,PUB28126595,RES69da4fa5,USEc6a2790c
PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,EMA,antibodies,Experimental Usage,PUB39996452,RESaec0c998,USEf5f63c70
PMID:30055648 | PMID:33356508 | PMID:39996452,10.1186/s13104-018-3630-0 | 10.1177/0963689720964383 | 10.1111/cns.70287,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. | Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,vimentin,antibodies,Experimental Usage,PUB5a3b3aae,RESb8669d9a,USEfc6f4809
PMID:33442015 | PMID:29847659 | PMID:41444363 | PMID:34010628 | PMID:18483311 | PMID:38127282,10.1038/s41591-020-01193-6 | 10.1167/iovs.17-22588 | 10.1038/s41598-025-32031-9 | 10.1016/j.stem.2021.04.029 | 10.1158/1535-7163.MCT-07-2335 | 10.1158/1078-0432.CCR-23-2548,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model. | Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,CD31,antibodies,Experimental Usage,PUBda93bd48,RES9a11aa6c,USE48f5fc87
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,AXL,antibodies,Experimental Usage,PUB33442015,RES8964361d,USE2c4e2ed2
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,pAXL,antibodies,Experimental Usage,PUB33442015,RESb003a6bb,USE99bb7ba0
PMID:33442015 | PMID:26904939,10.1038/s41591-020-01193-6 | 10.1016/j.celrep.2016.01.074,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,pGSK-3β,antibodies,Experimental Usage,PUB5d0c7649,RES55b84250,USEa10c4b9e
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,pMEK1/2,antibodies,Experimental Usage,PUB33442015,RES9e8706a6,USE82557306
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,CalbindinD-28K,antibodies,Experimental Usage,PUB29715273,RES390207c5,USE13988c2c
PMID:29715273 | PMID:24509877 | PMID:40684195,10.1371/journal.pone.0196726 | 10.1038/onc.2013.506 | 10.1186/s40478-025-02075-z,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,MBP,antibodies,Experimental Usage,PUBd5b61119,RES5e0ab2de,USEd636aa96
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,phospho-Histone H3,antibodies,Experimental Usage,PUB29715273,RES2b4213bb,USE56350c7b
PMID:29715273 | PMID:26219339,10.1371/journal.pone.0196726 | 10.18632/oncotarget.4858,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,NF2,antibodies,Experimental Usage,PUB50430a7b,RESa1a9bc9f,USE8c895ca1
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,phospho S518-Merlin,antibodies,Experimental Usage,PUB29715273,RESdd5ecbbb,USE6b25a06c
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,cyclophilin B,antibodies,Experimental Usage,PUB29715273,RES574f7c07,USEc2620e35
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,MAF,antibodies,Experimental Usage,PUB24509877,RESaf4299a0,USEeb1da77b
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,DEPTOR,antibodies,Experimental Usage,PUB24509877,RESd029e5c0,USEb07a2ab6
PMID:24509877 | PMID:21551250 | PMID:34040258 | PMID:40025578 | PMID:26904939 | PMID:40684195 | PMID:20049725,10.1038/onc.2013.506 | 10.1158/0008-5472.CAN-10-4577 | 10.1038/s41586-021-03580-6 | 10.1186/s40478-025-01965-6 | 10.1016/j.celrep.2016.01.074 | 10.1186/s40478-025-02075-z | 10.1002/emmm.200900027,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,S100β,antibodies,Experimental Usage,PUB7e596373,RES8fd8de15,USE74281947
PMID:24509877 | PMID:25535838,10.1038/onc.2013.506 | 10.7554/eLife.05151,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,BLBP,antibodies,Experimental Usage,PUB95797f8f,RES0a140ffa,USE7eb4c934
PMID:29941005 | PMID:30055648 | PMID:38744290 | PMID:33767727,10.1186/s13023-018-0843-1 | 10.1186/s13104-018-3630-0 | 10.1016/j.crmeth.2024.100772 | 10.3389/fgene.2021.603195,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening. | Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,CD34,antibodies,Experimental Usage,PUBa60263b0,RESd46d4a3b,USE648a04a6
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,RHAMM,antibodies,Experimental Usage,PUB23328114,RES1f79b663,USEb2a7902f
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,TPX2,antibodies,Experimental Usage,PUB23328114,RES8f06d8c1,USE4f12d539
PMID:18451155 | PMID:36322658 | PMID:40684195 | PMID:23328114 | PMID:36241865,10.1158/0008-5472.CAN-07-6867 | 10.1126/sciadv.abo5442 | 10.1186/s40478-025-02075-z | 10.18632/oncotarget.793 | 10.1038/s12276-022-00850-9,Pten haploinsufficiency accelerates formation of high-grade astrocytomas. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,nestin,antibodies,Experimental Usage,PUBa3a45c94,RES9d4d551b,USEeb1df798
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,AURKA,antibodies,Experimental Usage,PUB23328114,RES356dc29f,USE7349665a
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,phospho-AURKA (Thr288),antibodies,Experimental Usage,PUB23328114,RES9ac9bd7d,USE2e2f5645
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,p-histone H3 (Ser10),antibodies,Experimental Usage,PUB23328114,RES1c231528,USE9d8cfc8f
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,p-RHAMM (Thr703),antibodies,Experimental Usage,PUB23328114,RES91e33b58,USEc92fae5f
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,PDGFRβ,antibodies,Experimental Usage,PUB36322658,RES7b33fa2c,USEefa3193a
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,α-SMA,antibodies,Experimental Usage,PUB36322658,RES5dea785f,USE85f27a28
PMID:36322658 | PMID:33934112 | PMID:38203448,10.1126/sciadv.abo5442 | 10.1038/s41419-021-03716-6 | 10.3390/ijms25010277,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,GLUT1,antibodies,Experimental Usage,PUBa69e3baf,RES90de1082,USEce2bda7d
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,VEGFA,antibodies,Experimental Usage,PUB36322658,RESe3a67421,USE50c34e46
PMID:36322658 | PMID:36148553,10.1126/sciadv.abo5442 | 10.1093/brain/awac342,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,ALDH1A1,antibodies,Experimental Usage,PUBb6e40540,RES3b409488,USE4b77f0af
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,ZEB1,antibodies,Experimental Usage,PUB36322658,RESa68f116b,USE618e8853
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,IGFBP2,antibodies,Experimental Usage,PUB36322658,RES915d8f05,USEbc32a729
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,EYA4,antibodies,Experimental Usage,PUB36322658,RES045a0ef1,USE22fe9358
PMID:36730269 | PMID:36322658 | PMID:38744290 | PMID:36241865 | PMID:24371224,10.1371/journal.pone.0277305 | 10.1126/sciadv.abo5442 | 10.1016/j.crmeth.2024.100772 | 10.1038/s12276-022-00850-9 | 10.1158/0008-5472.CAN-13-2062,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,SOX2,antibodies,Experimental Usage,PUB30fbddd7,REScf44bde8,USE57f7dcf5
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,YAP/TAZ,antibodies,Experimental Usage,PUB36322658,RES65d7f768,USEe6b9df28
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,GAP43,antibodies,Experimental Usage,PUB21551250,RES14d1e90c,USE012b1df0
PMID:37520682 | PMID:28256556,10.1016/j.omtn.2023.06.018 | 10.1038/srep43315,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1. | An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,p75 NGFR,antibodies,Experimental Usage,PUBa802396b,RES26368382,USEcd5e143c
PMID:34040258 | PMID:40684195,10.1038/s41586-021-03580-6 | 10.1186/s40478-025-02075-z,NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,PDGFRα,antibodies,Experimental Usage,PUBc11e3c0b,RESfd85fbad,USEefe82e6f
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,NLGN3,antibodies,Experimental Usage,PUB34040258,RES204c0232,USE7962635b
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,ADAM10,antibodies,Experimental Usage,PUB34040258,RES7549e660,USEd3c11494
PMID:34040258 | PMID:30274821 | PMID:35511749 | PMID:38216572 | PMID:18367665,10.1038/s41586-021-03580-6 | 10.1016/j.ebiom.2018.09.042 | 10.1158/1535-7163.MCT-21-0947 | 10.1038/s41467-024-44755-9 | 10.1124/jpet.107.135830,NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,caspase-3,antibodies,Experimental Usage,PUB605bfd34,RES591bba0a,USE198dfbaf
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,tau 1,antibodies,Experimental Usage,PUB21949590,RES5b0e44ea,USE3e58c8b2
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,PTCH1,antibodies,Experimental Usage,PUB37164978,RESb840b5ec,USE6396d2c1
PMID:23535903 | PMID:26904939,10.1158/2159-8290.CD-13-0081 | 10.1016/j.celrep.2016.01.074,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.",,β-catenin,antibodies,Experimental Usage,PUB03367427,RESa2c1f6aa,USEcb29b2ce
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,neurofibromin/NF1,antibodies,Experimental Usage,PUB40590220,RES07ab6ac4,USE773836b5
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,FBXW11/bTrCP2,antibodies,Experimental Usage,PUB40590220,RES4081eb72,USE7fb0ae5c
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,pERK Thr202/Tyr204,antibodies,Experimental Usage,PUB40590220,RES042317be,USE4bf49dfd
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,synaptophysin,antibodies,Experimental Usage,PUB35945463,RESd8f7c7a2,USE5d7dba8c
PMID:35945463 | PMID:34065204 | PMID:30055648,10.1007/s00401-022-02478-5 | 10.3390/ijms22105367 | 10.1186/s13104-018-3630-0,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,p16,antibodies,Experimental Usage,PUB45a28293,RES4a7d607a,USE5718009b
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,histone H3 K27M mutant protein,antibodies,Experimental Usage,PUB35945463,RESe6d14f94,USE8335691b
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,histone H3 lysine 27 trimethylation,antibodies,Experimental Usage,PUB35945463,RESd7a03996,USE1ccb65f5
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,CD16/CD32,antibodies,Experimental Usage,PUB21681782,RESf9898ee5,USE99c8ae51
PMID:40217315 | PMID:24371224,10.1186/s13073-025-01462-4 | 10.1158/0008-5472.CAN-13-2062,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,CD24,antibodies,Experimental Usage,PUBd30358fb,RES7796feb5,USE412fd874
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,CD44,antibodies,Experimental Usage,PUB40217315,RESa0d55312,USEe2659e19
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,HLA Class I ABC,antibodies,Experimental Usage,PUB40217315,RES277d6905,USE83da2a39
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,MHC Class II,antibodies,Experimental Usage,PUB40217315,RES51130d57,USE068b5115
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,Pericentrin,antibodies,Experimental Usage,PUB38216587,RES34a2d178,USE5e748be0
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,γTubulin,antibodies,Experimental Usage,PUB38216587,RESbe15530c,USE12e8d23a
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,Acetylated Tubulin,antibodies,Experimental Usage,PUB38216587,RESa91bb7a3,USEd242987d
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CD13,antibodies,Experimental Usage,PUB29941005,RESdfc81273,USEf81bb651
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CD14,antibodies,Experimental Usage,PUB29941005,RESa9586e5d,USE54a851b9
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CD105,antibodies,Experimental Usage,PUB29941005,RES293a9c74,USEf9cd0010
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CD146,antibodies,Experimental Usage,PUB29941005,RES2fa0b729,USE65f0594b
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CD271,antibodies,Experimental Usage,PUB29941005,RESc53736cd,USE43294333
PMID:37990867 | PMID:24371224,10.1242/dmm.049861 | 10.1158/0008-5472.CAN-13-2062,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,OCT3/4,antibodies,Experimental Usage,PUBbeb9986f,RES2b21c16c,USEc2f3d023
PMID:37990867 | PMID:24371224,10.1242/dmm.049861 | 10.1158/0008-5472.CAN-13-2062,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,NANOG,antibodies,Experimental Usage,PUBbeb9986f,RES82dfaa22,USE68588658
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,MKK3,antibodies,Experimental Usage,PUB33436083,RES37b1764b,USEf1d292ef
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,p38,antibodies,Experimental Usage,PUB33436083,RESb2f77aa4,USE1839cf13
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,phospho-p38,antibodies,Experimental Usage,PUB33436083,RESe3d34716,USE981daed1
PMID:29438698 | PMID:36148553,10.1016/j.ccell.2018.01.005 | 10.1093/brain/awac342,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,TAZ,antibodies,Experimental Usage,PUBb89551ef,RES1cb732fb,USEc3832711
PMID:29438698 | PMID:36148553,10.1016/j.ccell.2018.01.005 | 10.1093/brain/awac342,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,YAP,antibodies,Experimental Usage,PUBb89551ef,RESbbcd83cb,USE6e59542f
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,TAZ/YAP,antibodies,Experimental Usage,PUB29438698,RES1adf9cf3,USEc49fbdd2
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,TEAD1,antibodies,Experimental Usage,PUB29438698,RES0628618a,USEc8b9b499
PMID:36730269 | PMID:36689660,10.1371/journal.pone.0277305 | 10.1073/pnas.2208960120,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,Ubiquitin,antibodies,Experimental Usage,PUB9c410e37,RES57c5ee50,USEd3e9a936
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,pCHEK1 S296,antibodies,Experimental Usage,PUB36730269,RESac7aa7d5,USEde256eb2
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,BMI1,antibodies,Experimental Usage,PUB36730269,RES10d6cc57,USE5993750e
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,H3K27Ac,antibodies,Experimental Usage,PUB36730269,RES2a850bcd,USE8f0deb3a
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,H3,antibodies,Experimental Usage,PUB36730269,RES8288e9cc,USE5b213190
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,CDK9,antibodies,Experimental Usage,PUB36730269,RESd35591d0,USEaff6790e
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,CPNase,antibodies,Experimental Usage,PUB36730269,RESc740cbf0,USE6da5f9de
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,MAG,antibodies,Experimental Usage,PUB36730269,RESab445341,USEed76d3fb
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,pS2 RNApol II,antibodies,Experimental Usage,PUB36730269,RESd30fedad,USE68e66e91
PMID:20195187 | PMID:28166733 | PMID:25043298,10.1097/MAO.0b013e3181d2777f | 10.1186/s12864-017-3519-7 | 10.1038/onc.2014.185,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. | A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma. | Oncogenic role of Merlin/NF2 in glioblastoma.,,EGFR,antibodies,Experimental Usage,PUB8a2c6895,RES27e711dd,USEf6b55a07
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,ErbB2,antibodies,Experimental Usage,PUB20195187,RESaf8fc51c,USEecbcbd50
PMID:20195187 | PMID:30055648 | PMID:36420221 | PMID:33658640,10.1097/MAO.0b013e3181d2777f | 10.1186/s13104-018-3630-0 | 10.1016/j.omtn.2022.10.026 | 10.1038/s41416-021-01270-8,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,actin,antibodies,Experimental Usage,PUB8c0d3348,RES57e7b524,USE248aa822
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,MPM-2,antibodies,Experimental Usage,PUB18413802,RES5e80c5b7,USE79801257
PMID:32948135 | PMID:30274821 | PMID:33032988 | PMID:18413802,10.1186/s12885-020-07397-w | 10.1016/j.ebiom.2018.09.042 | 10.1158/0008-5472.CAN-20-1365 | 10.1158/1535-7163.MCT-07-0518,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,cyclin D1,antibodies,Experimental Usage,PUB9567f62d,RES2469e2ff,USE61c485e0
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,B-Raf,antibodies,Experimental Usage,PUB18413802,RESf3da2a3a,USE28dcf312
PMID:34011935 | PMID:18413802,10.1038/s41419-021-03802-9 | 10.1158/1535-7163.MCT-07-0518,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,phospho-MEK1/2,antibodies,Experimental Usage,PUB4d9dbbee,RES56cbc605,USE6bfed2b3
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,phospho-Rb,antibodies,Experimental Usage,PUB18413802,RESe3470051,USE327c8917
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,MDM2,antibodies,Experimental Usage,PUB30274821,RESedc18f6a,USE3026e44c
PMID:20554030 | PMID:20551058,10.1016/j.jneuroim.2010.05.002 | 10.1158/0008-5472.CAN-09-3769,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,CXCL12,antibodies,Experimental Usage,PUBad1e66ae,RESa82348be,USE30d714a5
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,Endoglin,antibodies,Experimental Usage,PUB20554030,RESa0897cf3,USE9edb6456
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,p-PKA substrate,antibodies,Experimental Usage,PUB20554030,RES31a671bd,USE56045082
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,pS473-AKT,antibodies,Experimental Usage,PUB20554030,RES81cbda23,USEf6034440
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,CXCR4,antibodies,Experimental Usage,PUB20554030,RES7431729e,USE2cb27cd7
PMID:18451155 | PMID:20554030 | PMID:23685747 | PMID:36241865 | PMID:20551058,10.1158/0008-5472.CAN-07-6867 | 10.1016/j.jneuroim.2010.05.002 | 10.1038/ng.2641 | 10.1038/s12276-022-00850-9 | 10.1158/0008-5472.CAN-09-3769,Pten haploinsufficiency accelerates formation of high-grade astrocytomas. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,CNPase,antibodies,Experimental Usage,PUBad462c1c,RESaa2766e9,USE0b3a3714
PMID:20554030 | PMID:20551058,10.1016/j.jneuroim.2010.05.002 | 10.1158/0008-5472.CAN-09-3769,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,phosphorylated CXCR4,antibodies,Experimental Usage,PUBad1e66ae,RES611d451a,USEc7dbe893
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,phosphorylated PKA,antibodies,Experimental Usage,PUB37446790,RES6644d06e,USE317a6826
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,PKA,antibodies,Experimental Usage,PUB37446790,RES8ce6f221,USEd6ffc73f
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,phosphorylated CREB,antibodies,Experimental Usage,PUB37446790,RES73f6c6f3,USE2fc65018
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,CREB,antibodies,Experimental Usage,PUB37446790,RES6a324539,USE1c49f598
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,P-glycoprotein,antibodies,Experimental Usage,PUB40862755,RESacdab004,USE4726c08c
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,HSP70,antibodies,Experimental Usage,PUB36689660,RESb4c78593,USE161b78bf
PMID:21072183 | PMID:36689660,10.1371/journal.pone.0013791 | 10.1073/pnas.2208960120,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,GST,antibodies,Experimental Usage,PUBe2be218e,RESab0c80ad,USE42c9ee22
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,RASA1,antibodies,Experimental Usage,PUB36689660,RES71b47052,USE4149baf1
PMID:34065204 | PMID:37410426,10.3390/ijms22105367 | 10.1158/1078-0432.CCR-23-0749,"RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,RABL6A,antibodies,Experimental Usage,PUBf41f662a,RESd325898c,USE36d0dc92
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,FOXR2,antibodies,Experimental Usage,PUB23685747,RESdea41035,USEfda7b72c
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,Nuclear Pore Complex Proteins,antibodies,Experimental Usage,PUB38907342,RES0a2aae4e,USEac2560aa
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,HER1,antibodies,Experimental Usage,PUB40025578,RESa20e0309,USE70a6bba1
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,HER2,antibodies,Experimental Usage,PUB40025578,RES59ed1ce6,USE80141245
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,VEGFR2,antibodies,Experimental Usage,PUB40025578,RESdefc9468,USE26c9357a
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,B7H3,antibodies,Experimental Usage,PUB40025578,RES2522d88c,USEfc3c24a9
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,CD171,antibodies,Experimental Usage,PUB40025578,RES68dd6679,USE610fa15b
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,EGFRvIII,antibodies,Experimental Usage,PUB40025578,RES8f5959bf,USE3dbccf50
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,TGFβ1,antibodies,Experimental Usage,PUB40025578,RESee40cc49,USE62682617
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,CD8a,antibodies,Experimental Usage,PUB40025578,RES991e9ec7,USE6fd7f4e8
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,CD45RO,antibodies,Experimental Usage,PUB40025578,RESafc2b5b1,USE00fd5b98
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,CCR7,antibodies,Experimental Usage,PUB40025578,RESf66efdad,USE58ce38a4
PMID:21072183 | PMID:34011935,10.1371/journal.pone.0013791 | 10.1038/s41419-021-03802-9,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,Mek1/2,antibodies,Experimental Usage,PUB85e9ec84,RESdcac50d3,USEbf4d2ce8
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,MMP1,antibodies,Experimental Usage,PUB34011935,RESdfc91163,USEec872072
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,collagen I,antibodies,Experimental Usage,PUB34011935,RES26675054,USEb07669be
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,S100 protein,antibodies,Experimental Usage,PUB34011935,RES995cf037,USE6f0747fb
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,neurofibromin 1,antibodies,Experimental Usage,PUB41036607,RESbd6927a8,USE99d94341
PMID:18451155 | PMID:36241865,10.1158/0008-5472.CAN-07-6867 | 10.1038/s12276-022-00850-9,Pten haploinsufficiency accelerates formation of high-grade astrocytomas. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,β3-tubulin,antibodies,Experimental Usage,PUBbcb30524,RES70a8b825,USE59c45830
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,S100A10,antibodies,Experimental Usage,PUB26883872,RESac9490cc,USE934def57
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,Cdk1,antibodies,Experimental Usage,PUB35511749,RES7d6f2911,USE4c536ca3
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,phospho-Cdk1 Tyr15,antibodies,Experimental Usage,PUB35511749,RES46cb192b,USE3dbad74e
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,Acetyl-Histone H3 Lys18,antibodies,Experimental Usage,PUB35511749,RES3e18d538,USE4c8b532f
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,SAPK/JNK,antibodies,Experimental Usage,PUB35511749,RESa72276c6,USEb994ac8a
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,phospho-SAPK/JNK Thr183/Tyr185,antibodies,Experimental Usage,PUB35511749,RES1a7ea23f,USE10faa33e
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,p70S6 Kinase,antibodies,Experimental Usage,PUB35511749,RESff4d471f,USEcda4786e
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,phospho-p70 Thr389 S6 Kinase,antibodies,Experimental Usage,PUB35511749,RESc66f50fb,USE84e5f17b
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,phospho-S6 (Ser240/244),antibodies,Experimental Usage,PUB26219339,RES60ff2ad5,USE00029ead
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,phospho-S6 (S240/244),antibodies,Experimental Usage,PUB26219339,RES07a8cdd3,USEc448cf4a
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,phospho-p70 S6K (T389),antibodies,Experimental Usage,PUB26219339,RESc8586ba4,USE4671517a
PMID:26219339 | PMID:18483311,10.18632/oncotarget.4858 | 10.1158/1535-7163.MCT-07-2335,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,phospho-Akt (S473),antibodies,Experimental Usage,PUBa78b3e9b,RES8a6f28cf,USE70685913
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,phospho-NDRG1 (T346),antibodies,Experimental Usage,PUB26219339,RESfe15e53d,USE88e86110
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,SGK1,antibodies,Experimental Usage,PUB26219339,RESb1324e98,USEc32c056e
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,phospho-PAK1 (S144),antibodies,Experimental Usage,PUB26219339,RESa90659b5,USE403dab39
PMID:26219339 | PMID:21072183,10.18632/oncotarget.4858 | 10.1371/journal.pone.0013791,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,PAK1,antibodies,Experimental Usage,PUB11461b7c,RESc571eb6e,USE7a3710a9
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,4EBP1,antibodies,Experimental Usage,PUB26219339,RESb47238e9,USE439db15f
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,Rac1,antibodies,Experimental Usage,PUB26219339,RES649b79c1,USE0a945dfc
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,Rheb,antibodies,Experimental Usage,PUB26219339,RESb63edf74,USE2f7c4b18
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,tubulin,antibodies,Experimental Usage,PUB28166733,RESe0c78d5f,USE52107728
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,SUZ12,antibodies,Experimental Usage,PUB28166733,RES61579cf6,USE33b1d526
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,Pak2,antibodies,Experimental Usage,PUB21072183,RES1b440bc1,USEfc04b8d6
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,phospho-MEK1 (Ser298),antibodies,Experimental Usage,PUB21072183,RES1e4c03ff,USE74d380dd
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,phospho-Erk1/2 (Thr202/Tyr204),antibodies,Experimental Usage,PUB21072183,RESe2aabf37,USEfc9c807f
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,phospho-Akt (Thr308),antibodies,Experimental Usage,PUB21072183,REScd35b6ee,USE87004b11
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,phospho-Pak1–3 (Ser141),antibodies,Experimental Usage,PUB21072183,RES3be1adc5,USEfd723b50
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,DUSP6,antibodies,Experimental Usage,PUB33032988,RES94b43c2a,USEc5492d87
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,panendothelial cell antigen,antibodies,Experimental Usage,PUB24465906,RESa66e33b1,USE7f4cdba5
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,P-Stat3 (Y705),antibodies,Experimental Usage,PUB26904939,RESfd18767a,USE50273f64
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,P-Jak2,antibodies,Experimental Usage,PUB26904939,RES3b398732,USE0c75606d
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,Jak2,antibodies,Experimental Usage,PUB26904939,RES1e8b8f95,USEee6e8324
PMID:33658640 | PMID:26904939,10.1038/s41416-021-01270-8 | 10.1016/j.celrep.2016.01.074,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,p-STAT3,antibodies,Experimental Usage,PUB8bebb254,RES24bef5d0,USE4cf8c375
PMID:26904939 | PMID:33658640,10.1016/j.celrep.2016.01.074 | 10.1038/s41416-021-01270-8,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,Stat3,antibodies,Experimental Usage,PUBe2723987,RES62b3b5f1,USE490f9110
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,P-β-catenin,antibodies,Experimental Usage,PUB26904939,RES23d4b341,USE832c43e9
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,GSK3β,antibodies,Experimental Usage,PUB26904939,RES1c9725a0,USE78b166c0
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,CD16/32,antibodies,Experimental Usage,PUB34010628,RES9c0f565c,USEc2ffb9b3
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,Ter119,antibodies,Experimental Usage,PUB34010628,RES2e73d687,USE79f8a50a
PMID:18242513 | PMID:38175707,10.1016/j.ccr.2008.01.003 | 10.1172/jci.insight.168826,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. | Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,p75,antibodies,Experimental Usage,PUBc19b1118,RESf4ba79ee,USEed6dfac9
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,α4 integrin,antibodies,Experimental Usage,PUB18242513,RESf6b22719,USEd19e6251
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,phospho-histone-H3 (Ser 10),antibodies,Experimental Usage,PUB21216928,RES01cf14e4,USEfbf04444
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,"Various (phospho-S6, phospho-4EBP1, phospho-STAT3, AKT, etc.)",antibodies,Experimental Usage,PUB21216928,RES911d747c,USE9dab84f5
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,phospho-MEK,antibodies,Experimental Usage,PUB38714355,RESee138da8,USE55213653
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,RAD51,antibodies,Experimental Usage,PUB38714355,RES97c41b48,USEee44037e
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,BRCA2,antibodies,Experimental Usage,PUB38714355,RES20c609b2,USE2de6c90f
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,MGMT,antibodies,Experimental Usage,PUB38714355,RESfcb100ee,USE21c28cc1
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,yH2AX,antibodies,Experimental Usage,PUB38714355,RESfa9a86d4,USEf7ff5840
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,podoplanin,antibodies,Experimental Usage,PUB39472976,RES41b97a86,USEd6a8f055
PMID:40684195 | PMID:28256556,10.1186/s40478-025-02075-z | 10.1038/srep43315,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,F4/80,antibodies,Experimental Usage,PUB004ff77a,RES4f72f8ff,USEa705cb61
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,CSF1,antibodies,Experimental Usage,PUB28256556,RES92a72b6c,USE4f86ccb5
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,tomato,antibodies,Experimental Usage,PUB40684195,RES09036f50,USE60c72140
PMID:40684195 | PMID:38744290,10.1186/s40478-025-02075-z | 10.1016/j.crmeth.2024.100772,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,cKIT,antibodies,Experimental Usage,PUBe2712067,RES095b9860,USE00ec6e2b
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,POSTN,antibodies,Experimental Usage,PUB40684195,RES4e6d1ed2,USE95194cbd
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,TNC,antibodies,Experimental Usage,PUB40684195,RES6c6eee49,USEbab91af7
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,PGP9.5,antibodies,Experimental Usage,PUB40684195,RES267574a6,USE75753a2a
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,Aqp1,antibodies,Experimental Usage,PUB40684195,RESc904fbc0,USEa811c3c2
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,KIF11,antibodies,Experimental Usage,PUB32642733,RES48357fe6,USE7b7989d9
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,KIF15,antibodies,Experimental Usage,PUB32642733,RES7fbae4c2,USE891fa937
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,PGDS,antibodies,Experimental Usage,PUB17924978,RES7e8c01a3,USEdf1abdc7
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,phospho-S6K (T389),antibodies,Experimental Usage,PUB18483311,RESf62d489b,USEc855170b
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,S6K1,antibodies,Experimental Usage,PUB18483311,RES09483007,USEcc43fd0c
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,Mib1,antibodies,Experimental Usage,PUB18483311,RESd4b03c34,USE3a5dc0f9
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,PDE4A,antibodies,Experimental Usage,PUB20551058,RES43290f86,USE0eedefc9
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,LCA,antibodies,Experimental Usage,PUB20551058,RES71f69116,USE9deda7cc
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,phosphorylated protein kinase A substrate,antibodies,Experimental Usage,PUB20551058,RES5b353fd3,USE8aa29d74
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,MPZ,antibodies,Experimental Usage,PUB38175707,RES33ba01a0,USE7be93aa8
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,Survivin,antibodies,Experimental Usage,PUB38127282,RESf6c4721f,USE6ace30bc
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,CENPF,antibodies,Experimental Usage,PUB38127282,REScb3df69c,USE556f17d1
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,CD56,antibodies,Experimental Usage,PUB38744290,RESac325550,USEc87f94a6
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,CD117/c-kit,antibodies,Experimental Usage,PUB38744290,RES175e8b2f,USE03c281d9
PMID:38744290 | PMID:24371224,10.1016/j.crmeth.2024.100772 | 10.1158/0008-5472.CAN-13-2062,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,PanCytokeratin,antibodies,Experimental Usage,PUB0394f372,RESa0aa40fe,USE50578c51
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,S100A11,antibodies,Experimental Usage,PUB38744290,RES86d9433c,USE3e90e21f
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,beta tubulin,antibodies,Experimental Usage,PUB38216572,RESce0146a3,USEdb8b7d05
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,pMEK,antibodies,Experimental Usage,PUB38216572,RESa888ce86,USE87ae85a1
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,MEK,antibodies,Experimental Usage,PUB38216572,RES7a839d20,USEf01fe513
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,pPAK,antibodies,Experimental Usage,PUB38216572,RES2ee1c4dc,USE7254d445
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,Caspase-7,antibodies,Experimental Usage,PUB38216572,RES978125d3,USEb4613b1f
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Neurofilament,antibodies,Experimental Usage,PUB36148553,RES5446d869,USEaa41a273
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Pan-TEAD,antibodies,Experimental Usage,PUB36148553,RES32ff7468,USE59592e78
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,CTGF,antibodies,Experimental Usage,PUB36148553,RESf56d077c,USE6132a55c
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,Notch1,antibodies,Experimental Usage,PUB25043298,RES8c622520,USEd277c6f5
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,S518-Merlin,antibodies,Experimental Usage,PUB25043298,RESacca97fb,USE514b1949
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,"Na+,K+-ATPase",antibodies,Experimental Usage,PUB25043298,RES0b4af28b,USE58f48b1b
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,NeuroD1,antibodies,Experimental Usage,PUB32438526,RES3717c378,USE40586433
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,Phospho-Rb Ser 780,antibodies,Experimental Usage,PUB18367665,RESf68432fd,USEb2005f0a
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,Gal α 1-3Gal,antibodies,Experimental Usage,PUB15240917,RESb2a85439,USEfb3b7625
PMID:21963652 | PMID:24375753,10.1016/j.expneurol.2011.09.005 | 10.1002/ana.24093,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. | Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,DARPP32,antibodies,Experimental Usage,PUBec4874fd,RES543600e0,USE0b8b3f76
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,p-MAPK,antibodies,Experimental Usage,PUB21963652,RES95f5fde8,USEf6fedf66
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,total MAPK,antibodies,Experimental Usage,PUB21963652,RES9a6f498d,USE70a013d0
PMID:21963652 | PMID:24375753,10.1016/j.expneurol.2011.09.005 | 10.1002/ana.24093,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. | Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,p-DARPP32,antibodies,Experimental Usage,PUBec4874fd,RESde86bdcb,USE46415e81
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,Cy3/Cy5,antibodies,Experimental Usage,PUB31462295,RES52082172,USE71029290
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,DAXX,antibodies,Experimental Usage,PUB31462295,RESbe2f8f86,USE878b3e0f
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,"HLA-A,B,C",antibodies,Experimental Usage,PUB37246765,RES1cf6e883,USE4158ce15
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,H-2,antibodies,Experimental Usage,PUB37246765,RESb4a7a021,USE81aa28d5
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,human nuclei,antibodies,Experimental Usage,PUB37246765,RES6f43f945,USEcdd459c9
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,LAMA2,antibodies,Experimental Usage,PUB37770931,RES4e8a3b13,USEb4c0eaa4
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,SLC22A3,antibodies,Experimental Usage,PUB37770931,RES732818cd,USE81215b58
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,PRRX1,antibodies,Experimental Usage,PUB37770931,RESb1223481,USE4bc8f68b
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,Phospho-p44/42 ERK1/2,antibodies,Experimental Usage,PUB33978635,RES532f45cb,USEee881c8d
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,p44/42 ERK1/2,antibodies,Experimental Usage,PUB33978635,RES15bf2f0a,USE7e51f3a5
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,phosphor-p44/p42 MAPK (ERK1/2),antibodies,Experimental Usage,PUB33978635,RES66f08358,USE453df06c
PMID:37681415 | PMID:24375753,10.1172/jci.insight.168445 | 10.1002/ana.24093,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation. | Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,p-ERK1/2,antibodies,Experimental Usage,PUBc23b5d44,RES7cb40241,USE02b8f5f0
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,c-Met,antibodies,Experimental Usage,PUB24371224,RES93638eab,USEd6bc68f0
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,phosphorylated c-Met,antibodies,Experimental Usage,PUB24371224,RES139acc56,USE0eb1aee9
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,mesothelin,antibodies,Experimental Usage,PUB24371224,RESe54d42f8,USE7bb212d4
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,phospho P-Met,antibodies,Experimental Usage,PUB24371224,RES4a149182,USE6726368e
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,MAPK,antibodies,Experimental Usage,PUB24371224,RES01f1cfc3,USE2613008f
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,p55/MPP1,antibodies,Development,PUB19144871,RESe7a06774,USE5fbedb2b
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,NF-H,antibodies,Experimental Usage,PUB19144871,RES48ed0f4c,USE990250d7
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,Caspr,antibodies,Experimental Usage,PUB19144871,RESac2972ef,USEfc08dea0
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,CD11c,antibodies,Experimental Usage,PUB39321200,RES43ce0a78,USEfdda8e7a
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,CD19,antibodies,Experimental Usage,PUB39321200,RES2384302c,USEd65cf8fd
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,CD163,antibodies,Experimental Usage,PUB39321200,RESaaceec94,USEad99a1f5
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,CSF1R,antibodies,Experimental Usage,PUB39321200,RESe94aaee0,USE118fa9a5
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,ColIA,antibodies,Experimental Usage,PUB16835260,RES46535fcf,USE14806d82
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,Abl,antibodies,Experimental Usage,PUB16835260,RES35a33d78,USE40561666
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,c-abl,antibodies,Experimental Usage,PUB16835260,RESe98048bc,USE21ce141b
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,TGF-β,antibodies,Experimental Usage,PUB16835260,RES1e6f13aa,USE3c9952e6
PMID:25535838 | PMID:36241865,10.7554/eLife.05151 | 10.1038/s12276-022-00850-9,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,MAP2,antibodies,Experimental Usage,PUB0f212c55,RESe2ead219,USEb0f42422
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,NF-200,antibodies,Experimental Usage,PUB36241865,RESa4836a0d,USEf9c4b34a
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,P-mTOR,antibodies,Experimental Usage,PUB36241865,RES507d84ba,USEe59760ce
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Rictor,antibodies,Experimental Usage,PUB36241865,RES98c449f5,USE1dfc9e54
PMID:32948135 | PMID:36241865,10.1186/s12885-020-07397-w | 10.1038/s12276-022-00850-9,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,bcl2,antibodies,Experimental Usage,PUB6170711f,RES707a0e24,USE1582d960
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,myelin basic protein,antibodies,Experimental Usage,PUB36241865,RES7bb5eeb5,USE27ba56d7
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,pErbB2,antibodies,Experimental Usage,PUB24817309,RES2d7cc3d5,USEad650a2d
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,Calbindin,antibodies,Experimental Usage,PUB25535838,REScb249185,USE11b1df31
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,GABARα6,antibodies,Experimental Usage,PUB25535838,RES333167dd,USE5a5135f9
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,Tbr2,antibodies,Experimental Usage,PUB25535838,RES69535b82,USE9215833a
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,Calretinin,antibodies,Experimental Usage,PUB25535838,RESb77ee03b,USE172ccbd2
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,P27,antibodies,Experimental Usage,PUB25535838,RESd81fa405,USE4620582f
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,β-gal,antibodies,Experimental Usage,PUB25535838,RES01ade882,USE1b61cf83
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,COL4A,antibodies,Experimental Usage,PUB33591953,RES4437cb01,USE1a0a964d
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,histone H3 (tri methyl K27),antibodies,Experimental Usage,PUB33591953,RES75eb2838,USEcd91fe98
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,XBP1,antibodies,Experimental Usage,PUB38203448,RESa6e1cc6e,USE09b5cb63
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,XBP1u,antibodies,Experimental Usage,PUB38203448,RES7c8544c1,USE6ed62b37
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,XBP1s,antibodies,Experimental Usage,PUB38203448,RES1d756f1e,USE014004fd
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,Parkin,antibodies,Experimental Usage,PUB38203448,RES95bc3281,USE1e083836
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,PINK1,antibodies,Experimental Usage,PUB38203448,RESa91d0668,USE301d4117
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,ATP5H,antibodies,Experimental Usage,PUB38203448,RESb152fff0,USE6c1f7d59
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,p21,antibodies,Experimental Usage,PUB32948135,RESa53cd536,USE86e6b262
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,bcl6,antibodies,Experimental Usage,PUB32948135,RES80cfdb39,USEddd42d70
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,phospho-RB1 S807/811,antibodies,Experimental Usage,PUB37410426,RES132dfaee,USE4ec2fc13
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,kappa light chain,antibodies,Experimental Usage,PUB37410426,RESef57be98,USEa3a1cb5b
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,SIAH,antibodies,Experimental Usage,PUB37410426,RESe752c3d5,USE9752d807
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,Ref-1,antibodies,Experimental Usage,PUB33658640,RESed1cdb3c,USE79a5905f
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,NPcis cell line,cell_lines,Experimental Usage,PUB32642734,RES63492a0a,USE20dce609
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,BJFF.6,cell_lines,Experimental Usage,PUB35589737,RES46b2e4c2,USE0467cf9f
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,Normal human Schwann cells (Sciencell),cell_lines,Experimental Usage,PUB35589737,RES2b525570,USE4d3d7f6b
PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,TOP-10F' cells,cell_lines,Experimental Usage,PUB12057013,RES64383697,USE8e881073
PMID:38216123 | PMID:40507334,10.1016/j.molmet.2024.101876 | 10.3390/cancers17111852,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer. | Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,MCF7,cell_lines,Experimental Usage,PUB75cf961f,RES1945f01f,USEe662681c
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,Nf1 flox/flox calvaria osteoblasts,cell_lines,Experimental Usage,PUB20200958,RESd9a729dd,USEbf743cfb
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,DH10Bac cells,cell_lines,Experimental Usage,PUB31836666,RESdd4069b7,USE511ac279
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,BL21(DE3),cell_lines,Experimental Usage,PUB31836666,RES723c52d9,USE25fe230e
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,Sf9 cells,cell_lines,Experimental Usage,PUB31836666,RES649a81c4,USE28a9212b
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,Tni-FNL cells,cell_lines,Experimental Usage,PUB31836666,RESfe968e38,USEfdb8d8d4
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,NF1-null HEK293T cell line,cell_lines,Development,PUB31836666,REScf18c3c5,USEb518f376
PMID:40590220 | PMID:35789380 | PMID:31836666 | PMID:29402968 | PMID:31015291 | PMID:40225167 | PMID:34415582 | PMID:39269317 | PMID:23175151 | PMID:38216587 | PMID:20554030 | PMID:28166733 | PMID:33934112,10.1172/JCI188932 | 10.1158/2159-8290.CD-21-1671 | 10.1074/jbc.RA119.010934 | 10.1038/s41598-018-20894-0 | 10.1126/scisignal.aau8749 | 10.1155/2023/9628049 | 10.1002/glia.24075 | 10.1158/1078-0432.CCR-24-1750 | 10.1038/bjc.2012.518 | 10.1038/s41467-023-40408-5 | 10.1016/j.jneuroim.2010.05.002 | 10.1186/s12864-017-3519-7 | 10.1038/s41419-021-03716-6,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. | Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies. | Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins. | Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome. | Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury. | MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression. | Epigenetic reprogramming shapes the cellular landscape of schwannoma. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,HEK293T cells,cell_lines,Experimental Usage,PUB8eeda84c,RES7f062621,USE26eb8bde
PMID:38201517 | PMID:37164978 | PMID:24681606 | PMID:23685747 | PMID:41036607 | PMID:38203448 | PMID:23535903,10.3390/cancers16010089 | 10.1038/s41467-023-38432-6 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1158/1535-7163.MCT-24-1053 | 10.3390/ijms25010277 | 10.1158/2159-8290.CD-13-0081,"Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,S462TY,cell_lines,Experimental Usage,PUB4ea68a68,RESba144dfb,USE23b516fc
PMID:38201517 | PMID:18367665,10.3390/cancers16010089 | 10.1124/jpet.107.135830,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,iSC,cell_lines,Experimental Usage,PUB7b6d47c3,RES0f0c862a,USEdc9511fb
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,A549,cell_lines,Experimental Usage,PUB38201517,RESd602b122,USE43e178d0
PMID:38201517 | PMID:41022755 | PMID:39269317 | PMID:18367665 | PMID:37246765 | PMID:33658640 | PMID:24824755 | PMID:39129390 | PMID:18413802 | PMID:24681606 | PMID:23685747 | PMID:20049725 | PMID:32642733 | PMID:18483311 | PMID:38127282 | PMID:38216572 | PMID:38203448 | PMID:23535903 | PMID:41036607 | PMID:33032988,10.3390/cancers16010089 | 10.1038/s41467-025-63619-4 | 10.1158/1078-0432.CCR-24-1750 | 10.1124/jpet.107.135830 | 10.1093/neuonc/noad097 | 10.1038/s41416-021-01270-8 | 10.1371/journal.pone.0096733 | 10.1002/1878-0261.13704 | 10.1158/1535-7163.MCT-07-0518 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1002/emmm.200900027 | 10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-07-2335 | 10.1158/1078-0432.CCR-23-2548 | 10.1038/s41467-024-44755-9 | 10.3390/ijms25010277 | 10.1158/2159-8290.CD-13-0081 | 10.1158/1535-7163.MCT-24-1053 | 10.1158/0008-5472.CAN-20-1365,"Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. | Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.",,ST88-14,cell_lines,Experimental Usage,PUBe87ca157,RES8c79577c,USEa42d3652
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,MCF10A,cell_lines,Experimental Usage,PUB38201517,RES13ccb15b,USE12937665
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,murine NF2 −/− Schwann cell line,cell_lines,Experimental Usage,PUB30617350,RESd6bdbe98,USEf3b3f0a3
PMID:21111000 | PMID:38216587 | PMID:30617350 | PMID:30274821,10.1016/j.jneumeth.2010.10.021 | 10.1038/s41467-023-40408-5 | 10.1038/s41596-018-0105-7 | 10.1016/j.ebiom.2018.09.042,"A novel imaging-compatible sciatic nerve schwannoma model. | Epigenetic reprogramming shapes the cellular landscape of schwannoma. | A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.",,HEI-193,cell_lines,Experimental Usage,PUBe7e07743,RES83633cde,USE2590e7b8
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,ipNF05.5 (mixed clone),cell_lines,Experimental Usage,PUB35741605,RES27a80654,USE46cc18b1
PMID:35741605 | PMID:40723243,10.3390/brainsci12060720 | 10.3390/cancers17142359,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas. | The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,ipNF05.5 (single clone),cell_lines,Experimental Usage,PUBad2ac02e,RESc8a1bf77,USE065855b5
PMID:35741605 | PMID:39129390 | PMID:40862755 | PMID:36689660 | PMID:39061138 | PMID:40723243,10.3390/brainsci12060720 | 10.1002/1878-0261.13704 | 10.3390/cells14161276 | 10.1073/pnas.2208960120 | 10.3390/cancers16142498 | 10.3390/cancers17142359,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization. | A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids. | The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,ipNF95.11bC,cell_lines,Experimental Usage,PUB2b259282,RES8555ee4e,USEd7793201
PMID:35741605 | PMID:33934112 | PMID:33442015 | PMID:38136356,10.3390/brainsci12060720 | 10.1038/s41419-021-03716-6 | 10.1038/s41591-020-01193-6 | 10.3390/cancers15245811,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF95.6,cell_lines,Experimental Usage,PUB8c0a7b32,RES53c1db9a,USEd593b905
PMID:35741605 | PMID:39129390 | PMID:38136356 | PMID:40723243,10.3390/brainsci12060720 | 10.1002/1878-0261.13704 | 10.3390/cancers15245811 | 10.3390/cancers17142359,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency. | The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,ipnNF95.11c,cell_lines,Experimental Usage,PUBad0fc128,RESd7276863,USEf306d295
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,COS-7,cell_lines,Experimental Usage,PUB40225167,RESabb7add4,USE88d95712
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,Nf1-/- mouse embryo fibroblasts,cell_lines,Experimental Usage,PUB21199799,RESabd0cc70,USE4e3402ae
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,T265-2c,cell_lines,Experimental Usage,PUB24824755,RES7d7c375d,USEb4c288c9
PMID:24824755 | PMID:20049725 | PMID:32642733 | PMID:18483311,10.1371/journal.pone.0096733 | 10.1002/emmm.200900027 | 10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-07-2335,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,90-8,cell_lines,Experimental Usage,PUB168d0863,RES4d55b268,USEba2110d2
PMID:24040940 | PMID:33032988,10.1186/1479-5876-11-213 | 10.1158/0008-5472.CAN-20-1365,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF96.2,cell_lines,Experimental Usage,PUB11a16d05,RES68239221,USE28504605
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,NF02.2,cell_lines,Experimental Usage,PUB24040940,RESc0c71d85,USEac0b96f6
PMID:24040940 | PMID:33032988,10.1186/1479-5876-11-213 | 10.1158/0008-5472.CAN-20-1365,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF94.3,cell_lines,Experimental Usage,PUB11a16d05,RESae0432c8,USE88fcd04a
PMID:33673681 | PMID:30531922,10.3390/cancers13050999 | 10.1038/s41591-018-0263-8,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of | The molecular landscape of glioma in patients with Neurofibromatosis 1.,,HEK293 cells,cell_lines,Experimental Usage,PUBbb685c75,RESbaa9fdad,USE851038fd
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and,,LLC-PK1 ATCC CL-101,cell_lines,Experimental Usage,PUB34630515,RES98351e60,USE07500ce2
PMID:33934112 | PMID:32457840,10.1038/s41419-021-03716-6 | 10.3389/fonc.2020.00687,"HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,MiaPaCa-2,cell_lines,Experimental Usage,PUBd038b8e3,RES3224a315,USE927e2c1c
PMID:33934112 | PMID:32457840,10.1038/s41419-021-03716-6 | 10.3389/fonc.2020.00687,"HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,PANC1,cell_lines,Experimental Usage,PUBd038b8e3,RES928f1713,USE77a1a2bd
PMID:33934112 | PMID:32457840,10.1038/s41419-021-03716-6 | 10.3389/fonc.2020.00687,"HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,BxPc3,cell_lines,Experimental Usage,PUBd038b8e3,RESd23e6c85,USE328c1abc
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,AsPC-1,cell_lines,Experimental Usage,PUB32457840,RES660e82ea,USE26a6d7b7
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,HPDE H6c7,cell_lines,Experimental Usage,PUB32457840,RES00c86d4a,USE207b3c73
PMID:33273014 | PMID:28126595 | PMID:26219339 | PMID:36148553,10.1074/jbc.RA120.014960 | 10.1016/j.ebiom.2017.01.020 | 10.18632/oncotarget.4858 | 10.1093/brain/awac342,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Ben-Men-1,cell_lines,Experimental Usage,PUBbfed82de,RES8ba7d57b,USE8d30b557
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,AC-CRISPR,cell_lines,Experimental Usage,PUB33273014,RESc40180a9,USEdd7577b2
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,MN1-LF,cell_lines,Experimental Usage,PUB33273014,RESd4d873f7,USE4e7acdc4
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,H358 cells,cell_lines,Experimental Usage,PUB38502231,RES6448cbce,USEf2f11513
PMID:41022755 | PMID:32383545 | PMID:33658640 | PMID:38502231 | PMID:23328114 | PMID:37164978 | PMID:24681606 | PMID:23685747 | PMID:30055648 | PMID:20049725 | PMID:32642733 | PMID:18483311 | PMID:38127282 | PMID:41001593 | PMID:32948135 | PMID:37410426 | PMID:23535903 | PMID:35511749,10.1038/s41467-025-63619-4 | 10.15252/embr.201949117 | 10.1038/s41416-021-01270-8 | 10.1172/JCI176748 | 10.18632/oncotarget.793 | 10.1038/s41467-023-38432-6 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1186/s13104-018-3630-0 | 10.1002/emmm.200900027 | 10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-07-2335 | 10.1158/1078-0432.CCR-23-2548 | 10.1080/23723556.2025.2561292 | 10.1186/s12885-020-07397-w | 10.1158/1078-0432.CCR-23-0749 | 10.1158/2159-8290.CD-13-0081 | 10.1158/1535-7163.MCT-21-0947,"Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression. | Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor. | Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.",,S462,cell_lines,Experimental Usage,PUBece01cc9,RES7787dd40,USEaf218568
PMID:38502231 | PMID:35393510,10.1172/JCI176748 | 10.1038/s41418-022-00991-4,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,cis MPNST cell line,cell_lines,Experimental Usage,PUB323fc5a7,RESbf9e0bf2,USEdf3c9075
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,HTS-Luc MPNST cell line,cell_lines,Experimental Usage,PUB38502231,RES9709e143,USEec716322
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,pNF9511bc,cell_lines,Experimental Usage,PUB41022755,RESd2d7bbb3,USEe28f57d8
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,ipNF03.3,cell_lines,Experimental Usage,PUB41022755,RES4029030f,USE53f3bfaf
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,ipn023λ,cell_lines,Experimental Usage,PUB41022755,RES22f213dc,USE2373d42f
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,RHT92,cell_lines,Experimental Usage,PUB41022755,RESbf7021d2,USEcca70cd9
PMID:41022755 | PMID:38714355,10.1038/s41467-025-63619-4 | 10.1158/1535-7163.MCT-23-0510,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,LN229,cell_lines,Experimental Usage,PUB058134e4,RESec88ccdf,USEae989ec4
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,2V6.11,cell_lines,Experimental Usage,PUB41022755,RES0162cd28,USEeb534f55
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,FiPS,cell_lines,Experimental Usage,PUB41022755,RESd0d2a3a9,USE5dac34d6
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,"NF1−/−−/− edited FiPS Ctrl1-SV4F-7, D12",cell_lines,Experimental Usage,PUB41022755,RESdc14408d,USEc41e640f
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,3PNF_SiPSsv_MM_11,cell_lines,Experimental Usage,PUB41022755,RES63dfec23,USEa5f0cfc5
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,M724,cell_lines,Experimental Usage,PUB39269317,RES0b303b9d,USE89ad1748
PMID:39269317 | PMID:23175151 | PMID:29438698 | PMID:40025578 | PMID:36322658 | PMID:35511749 | PMID:32642733 | PMID:38216572,10.1158/1078-0432.CCR-24-1750 | 10.1038/bjc.2012.518 | 10.1016/j.ccell.2018.01.005 | 10.1186/s40478-025-01965-6 | 10.1126/sciadv.abo5442 | 10.1158/1535-7163.MCT-21-0947 | 10.1093/noajnl/vdz061 | 10.1038/s41467-024-44755-9,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,SNF96.2,cell_lines,Experimental Usage,PUBb5d6cacb,RES65ffa5bf,USE9753d0c6
PMID:39269317 | PMID:35789380,10.1158/1078-0432.CCR-24-1750 | 10.1158/2159-8290.CD-21-1671,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,M1,cell_lines,Experimental Usage,PUB2bd6c16e,RESa3b8883e,USE1330a1cd
PMID:39269317 | PMID:35789380,10.1158/1078-0432.CCR-24-1750 | 10.1158/2159-8290.CD-21-1671,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,M3,cell_lines,Experimental Usage,PUB2bd6c16e,RESdc69ceb0,USEc019d873
PMID:39269317 | PMID:35789380,10.1158/1078-0432.CCR-24-1750 | 10.1158/2159-8290.CD-21-1671,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,M4,cell_lines,Experimental Usage,PUB2bd6c16e,RESd9806b0b,USE18f9c194
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,M5,cell_lines,Experimental Usage,PUB39269317,RESa330fc30,USE81ca75b2
PMID:39269317 | PMID:35789380,10.1158/1078-0432.CCR-24-1750 | 10.1158/2159-8290.CD-21-1671,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,M6,cell_lines,Experimental Usage,PUB2bd6c16e,RES15880533,USE1588d361
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,Drosophila Schneider (S2R+) cells,cell_lines,Experimental Usage,PUB39129390,RES65662a6d,USE20b1e11a
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,dNF1‐KO,cell_lines,Development,PUB39129390,REScd43134d,USEa37cc84c
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,hTERT ipn02.3 2λ CRL‐3392,cell_lines,Experimental Usage,PUB39129390,RES2fe12b13,USE235c3484
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,"ipnNF09.4 (hTERT NF1 ipnNF09.4, RRID: CVCL_UI73)",cell_lines,Experimental Usage,PUB39129390,RES5e08b0cc,USEf920c01b
PMID:39129390 | PMID:40862755 | PMID:39061138 | PMID:33658640,10.1002/1878-0261.13704 | 10.3390/cells14161276 | 10.3390/cancers16142498 | 10.1038/s41416-021-01270-8,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures. | A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,"ipNF05.5 (hTERT NF1 ipNF05.5, RRID: CVCL_UI71)",cell_lines,Experimental Usage,PUB6189f9ee,RES5de742ed,USEa1e23e57
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,U2OS,cell_lines,Experimental Usage,PUB30531922,RES0242f8da,USE9526e844
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,Human meningeal cells (HMC),cell_lines,Experimental Usage,PUB28126595,RES35bbc5c9,USE569c32ef
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,lymphoblastoid cell lines,cell_lines,Experimental Usage,PUB25329635,RESb9449add,USE3012b2fe
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,OLN93 mouse oligodendrocyte cell line,cell_lines,Experimental Usage,PUB29715273,RES33b4d8cc,USEe55cf007
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,SC4-immortalized Nf2-/- primary Schwann cells,cell_lines,Experimental Usage,PUB29715273,RES4bb1d196,USE4cc49875
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,RT4-D6PT2 schwannoma cell line,cell_lines,Experimental Usage,PUB29715273,RESc23eadf1,USE8ab97592
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,TC620 human oligodendroglioma cell line,cell_lines,Experimental Usage,PUB29715273,RES6b2e8a99,USE04b61aa3
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,Normal human Schwann cells (NHSC),cell_lines,Experimental Usage,PUB24509877,RESb2bfc67f,USEe956f922
PMID:24509877 | PMID:18413802,10.1038/onc.2013.506 | 10.1158/1535-7163.MCT-07-0518,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,MPNST cell lines,cell_lines,Experimental Usage,PUB0329016d,RES8bfa4d28,USE764caaf5
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,MPNST 88-14 cells,cell_lines,Experimental Usage,PUB24509877,RES8fea907c,USE17f07bde
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,MPNST S462-TY cells,cell_lines,Experimental Usage,PUB24509877,RES6703798b,USEe282f21f
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,2884 cell line,cell_lines,Experimental Usage,PUB23328114,RES08493b1a,USEcfab1094
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,2885 cell line,cell_lines,Experimental Usage,PUB23328114,RES9228949e,USE8aa8f120
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,hTERT NF1 ipn02.3 2λ,cell_lines,Experimental Usage,PUB36322658,RESa4c9d0d2,USE139dc597
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,ipn95.11bC,cell_lines,Experimental Usage,PUB36322658,RESc11f75a8,USEc6d3f939
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,MPNST642,cell_lines,Experimental Usage,PUB36322658,RESfc99283a,USEcbc852ac
PMID:36322658 | PMID:37164978 | PMID:24681606 | PMID:23685747 | PMID:30055648 | PMID:41001593 | PMID:38203448 | PMID:32948135 | PMID:23535903,10.1126/sciadv.abo5442 | 10.1038/s41467-023-38432-6 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1186/s13104-018-3630-0 | 10.1080/23723556.2025.2561292 | 10.3390/ijms25010277 | 10.1186/s12885-020-07397-w | 10.1158/2159-8290.CD-13-0081,"Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,T265,cell_lines,Experimental Usage,PUB556fe557,RES46d7227b,USE10612592
PMID:36322658 | PMID:37164978 | PMID:24681606 | PMID:23685747 | PMID:20049725 | PMID:32642733 | PMID:18483311 | PMID:38203448 | PMID:37410426 | PMID:23535903 | PMID:35511749 | PMID:33032988,10.1126/sciadv.abo5442 | 10.1038/s41467-023-38432-6 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1002/emmm.200900027 | 10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-07-2335 | 10.3390/ijms25010277 | 10.1158/1078-0432.CCR-23-0749 | 10.1158/2159-8290.CD-13-0081 | 10.1158/1535-7163.MCT-21-0947 | 10.1158/0008-5472.CAN-20-1365,"Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.",,STS26T,cell_lines,Experimental Usage,PUB3337a5d4,RES74567322,USE4acb3c62
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,ipn97.4 immortalized human Schwann cells,cell_lines,Experimental Usage,PUB39890807,RES5718db6a,USE21b47247
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,Schwann cells,cell_lines,Experimental Usage,PUB37520682,RES4bc847e6,USEef93c1c4
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,optic glioma cells,cell_lines,Experimental Usage,PUB34040258,RES5ca9707b,USE6f371e63
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,HSC1λ,cell_lines,Experimental Usage,PUB37164978,RESaed6fdb0,USE1c445731
PMID:37164978 | PMID:38136356,10.1038/s41467-023-38432-6 | 10.3390/cancers15245811,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF06.2A,cell_lines,Experimental Usage,PUBc1ed5c82,RES2d65bb8e,USEd3a3f6c3
PMID:40590220 | PMID:36420221 | PMID:32383545,10.1172/JCI188932 | 10.1016/j.omtn.2022.10.026 | 10.15252/embr.201949117,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype | Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,HeLa cells,cell_lines,Experimental Usage,PUB3f27522a,RES1de4e591,USEd9981329
PMID:32383545 | PMID:37446790,10.15252/embr.201949117 | 10.3390/molecules28135128,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca | Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,C2C12 cells,cell_lines,Experimental Usage,PUB4be6d563,RES27fb92bc,USE1e0d5b59
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,NF1-1 hiPSC line,cell_lines,Experimental Usage,PUB38481529,REScb018edb,USE68abe399
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,NF1-2 hiPSC line,cell_lines,Experimental Usage,PUB38481529,RES44e8d8f6,USE32eaea33
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,WT-1 hiPSC line,cell_lines,Experimental Usage,PUB38481529,RES71ae386c,USE9d1a4c8f
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,WT-2 hiPSC line,cell_lines,Experimental Usage,PUB38481529,RES637f1fbc,USEae0b4b7b
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,LUVA cells,cell_lines,Experimental Usage,PUB40590220,RESbb2011d5,USE8538e7f5
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,"Human Schwann Cells (HSC, ScienCell Research Laboratories #1700)",cell_lines,Experimental Usage,PUB38216587,RES8ff373eb,USE911fa3f2
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,"Mouse Schwann Cells (MSC, ScienCell Research Laboratories #M1700-57)",cell_lines,Experimental Usage,PUB38216587,RESeb9e3bd3,USE7b997fb1
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,NF37,cell_lines,Experimental Usage,PUB29941005,RESbaf0c6ad,USE7b71047b
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,NF87,cell_lines,Experimental Usage,PUB29941005,RES4f830669,USEac4cb954
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CT10,cell_lines,Experimental Usage,PUB29941005,RES0bb17402,USEc2ecf0c2
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CT11,cell_lines,Experimental Usage,PUB29941005,RES2566bbac,USE2bcfee78
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CT12,cell_lines,Experimental Usage,PUB29941005,RESe416a28a,USE2e862478
PMID:29438698 | PMID:38216572,10.1016/j.ccell.2018.01.005 | 10.1038/s41467-024-44755-9,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,SNF02.2,cell_lines,Experimental Usage,PUB61b2d569,RES359bb0bd,USE25d02b32
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,TM-31,cell_lines,Experimental Usage,PUB36730269,RES7b299c69,USE646ae8f4
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,LN319,cell_lines,Experimental Usage,PUB36730269,RESecb75ef8,USE23f66ed2
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,17,cell_lines,Experimental Usage,PUB36730269,RESa28a03a6,USE44cab8cc
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,5653,cell_lines,Experimental Usage,PUB36730269,RESa015d578,USEefb0eeb6
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,5746,cell_lines,Experimental Usage,PUB36730269,RESe4bdb201,USE31ccf646
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,"Human Schwann cells (HSC; ScienCell, Carlsbad, CA)",cell_lines,Experimental Usage,PUB20195187,RES2c34b788,USEb734a327
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,LS141,cell_lines,Experimental Usage,PUB18413802,RES310ed0e3,USE16100690
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,DDLS,cell_lines,Experimental Usage,PUB18413802,RES4ea34695,USEa5283281
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,Human Schwann cells (HSCs),cell_lines,Experimental Usage,PUB30274821,RESa6f1e455,USE4e5d18e2
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,RT4-D6P2T schwannoma cells,cell_lines,Experimental Usage,PUB30274821,RES8053683d,USE4ad7d94d
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,LN428 human glioblastoma multiforme (GBM) cell line,cell_lines,Experimental Usage,PUB20554030,RES6e47acf7,USE333c55cd
PMID:28831766,10.1007/s12104-017-9768-1,NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.,,BL21(DE3) Star,cell_lines,Experimental Usage,PUB28831766,RES30a714b9,USEe849debd
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,NF1-null 293T cells,cell_lines,Experimental Usage,PUB36689660,REScc45049c,USE6a479bca
PMID:28392281 | PMID:34065204,10.1016/j.expneurol.2017.04.001 | 10.3390/ijms22105367,Human stem cell modeling in neurofibromatosis type 1 (NF1). | RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,mouse embryonic fibroblasts (MEFs),cell_lines,Experimental Usage,PUB46ecf57f,RES2ab2c141,USEd4f59435
PMID:38000020 | PMID:38127282,10.1126/sciadv.adg8876 | 10.1158/1078-0432.CCR-23-2548,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,JH-2-002,cell_lines,Experimental Usage,PUBcb7cca4f,RES06bbbd46,USE9e14b0af
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,JH-2-031,cell_lines,Experimental Usage,PUB38000020,RES748525c7,USE150ad7b3
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,JH-2-079c,cell_lines,Experimental Usage,PUB38000020,RES24aca845,USE882ad06d
PMID:38000020 | PMID:38127282,10.1126/sciadv.adg8876 | 10.1158/1078-0432.CCR-23-2548,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,JH-2-103,cell_lines,Experimental Usage,PUBcb7cca4f,RES76c34922,USE8e151dab
PMID:23685747 | PMID:41036607,10.1038/ng.2641 | 10.1158/1535-7163.MCT-24-1053,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,iHSCs,cell_lines,Experimental Usage,PUB2c295693,RES9da57d39,USE1e0226ed
PMID:23685747 | PMID:40025578,10.1038/ng.2641 | 10.1186/s40478-025-01965-6,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,K562,cell_lines,Experimental Usage,PUB62b99413,RESfdd6b370,USEcf430d87
PMID:41564118 | PMID:38907342,10.1371/journal.pone.0340183 | 10.1186/s40478-024-01821-z,"Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,icNF97.2a,cell_lines,Development,PUBe5a5ea03,RES6156e612,USE4542402e
PMID:41564118 | PMID:38907342,10.1371/journal.pone.0340183 | 10.1186/s40478-024-01821-z,"Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,icNF97.2b,cell_lines,Development,PUBe5a5ea03,RESe3697125,USE945c1070
PMID:41564118 | PMID:38907342,10.1371/journal.pone.0340183 | 10.1186/s40478-024-01821-z,"Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,icNF98.4d,cell_lines,Development,PUBe5a5ea03,RES0583d402,USE09c5fb64
PMID:40025578 | PMID:25026211 | PMID:26219339,10.1186/s40478-025-01965-6 | 10.1016/j.ccr.2014.05.001 | 10.18632/oncotarget.4858,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment. | Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,293T cells,cell_lines,Experimental Usage,PUBd9b452bd,RES63f2af1e,USEde46f218
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,HFFs,cell_lines,Experimental Usage,PUB40025578,RESd6afe7f8,USE5a51b9a4
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,NCI-H266,cell_lines,Experimental Usage,PUB40025578,RES32251ebd,USE01a6d9f6
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,Neurofibromatosis 1 fibroblasts,cell_lines,Experimental Usage,PUB34011935,RES015a8eda,USE6992c8e1
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-SP-01,cell_lines,Experimental Usage,PUB35511749,RESf6ce18b7,USEb3b752a7
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-NF1-08,cell_lines,Experimental Usage,PUB35511749,RESebfbb29f,USE4257d43b
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-NF1-9,cell_lines,Experimental Usage,PUB35511749,RES62b59d33,USE3218cb28
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,HS-PSS,cell_lines,Experimental Usage,PUB35511749,RESb82893e4,USEcbc6e056
PMID:32642733 | PMID:35511749,10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-21-0947,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,HS-Sch-2,cell_lines,Experimental Usage,PUBbaf4f291,RES871bb6fa,USEdf1ac38e
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,Human Foreskin Fibroblast (HFF),cell_lines,Experimental Usage,PUB35511749,RES94d99650,USE41e236ae
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,ipNF95.11b C-RFP,cell_lines,Experimental Usage,PUB39061138,RESdf9174e6,USEa2f16f1d
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,AC007-hTERT,cell_lines,Experimental Usage,PUB26219339,RESca37f0db,USE31cc8ad8
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,AC028,cell_lines,Experimental Usage,PUB26219339,RESeae42705,USE2927d574
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,U87-MG,cell_lines,Experimental Usage,PUB28166733,RES02cd4945,USE90d9923f
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,Meso-33,cell_lines,Experimental Usage,PUB25026211,RES7ec195a8,USE1414fbea
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,FC-1801,cell_lines,Experimental Usage,PUB25026211,RESba34146c,USE54c80388
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,NIH-3T3,cell_lines,Experimental Usage,PUB21072183,RES331e6cdf,USEe191390a
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,φNX packaging cell line,cell_lines,Experimental Usage,PUB21072183,RES27693bb3,USE1730448d
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,H1838,cell_lines,Experimental Usage,PUB33032988,RESc7b181eb,USE47348435
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,WM3918,cell_lines,Experimental Usage,PUB33032988,RES2a6648a2,USE95cf342e
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,M308,cell_lines,Experimental Usage,PUB33032988,RESa889216f,USE53abb4be
PMID:18367665 | PMID:33658640 | PMID:33032988,10.1124/jpet.107.135830 | 10.1038/s41416-021-01270-8 | 10.1158/0008-5472.CAN-20-1365,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF90-8,cell_lines,Experimental Usage,PUBf8e8a007,RES7d84433c,USE23a7af8a
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF10.1,cell_lines,Experimental Usage,PUB33032988,RES8cd5f20e,USE04c1b992
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF11.1,cell_lines,Experimental Usage,PUB33032988,RES437abbbb,USEe1b86666
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,K4622 grade II glioma cell line,cell_lines,Experimental Usage,PUB21216928,RESdb3ab40e,USE4cd892e2
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,HSR-GBM1,cell_lines,Experimental Usage,PUB38714355,RES0e69a08f,USE95898ca0
PMID:39472976 | PMID:38714355,10.1186/s40478-024-01875-z | 10.1158/1535-7163.MCT-23-0510,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,JHH-520 cell line,cell_lines,Experimental Usage,PUBcf268d95,RES7d16532b,USE71d59fc2
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,JHU-0879,cell_lines,Experimental Usage,PUB38714355,RES7cfe241c,USEbdec9c44
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,JHU-1016B,cell_lines,Experimental Usage,PUB38714355,RESd39ec166,USE26779c07
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,JHH-136,cell_lines,Experimental Usage,PUB38714355,RESe586e098,USE300ed0ca
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,B76,cell_lines,Experimental Usage,PUB38714355,RES7ba5993a,USE0a1bd05a
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,NGT-41,cell_lines,Experimental Usage,PUB38714355,RES8d501cc9,USEa0ec475e
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,NMCG-1,cell_lines,Experimental Usage,PUB38714355,RES240e5436,USE4c853b69
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,DBTRG,cell_lines,Experimental Usage,PUB38714355,RES25623437,USE1006d2f9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,T98G,cell_lines,Experimental Usage,PUB38714355,RESd8d494a3,USE025ebefd
PMID:32419643 | PMID:33934112 | PMID:25043298,10.1177/1533033820919759 | 10.1038/s41419-021-03716-6 | 10.1038/onc.2014.185,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | Oncogenic role of Merlin/NF2 in glioblastoma.,,U251,cell_lines,Experimental Usage,PUB396b63ee,RES874fed52,USE034fc5bc
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,PNF-derived Schwann cells,cell_lines,Experimental Usage,PUB25340526,RES828ab613,USE7366790e
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,GBM1 cell line,cell_lines,Experimental Usage,PUB39472976,RES9927ef7e,USE31882738
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,JHH-0879 cell line,cell_lines,Experimental Usage,PUB39472976,RESbd60dbd9,USEc07c044b
PMID:20049725 | PMID:18483311,10.1002/emmm.200900027 | 10.1158/1535-7163.MCT-07-2335,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,S520,cell_lines,Experimental Usage,PUBbd46e5f9,RESeba89533,USE70f00be1
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,88-3,cell_lines,Experimental Usage,PUB20049725,RES82831da4,USE9bca7ecf
PMID:20049725 | PMID:18483311,10.1002/emmm.200900027 | 10.1158/1535-7163.MCT-07-2335,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,YST1,cell_lines,Experimental Usage,PUBbd46e5f9,RESc41540f6,USE13fdef44
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,icNF98.4c,cell_lines,Development,PUB41564118,RES1f1514dd,USE388aeb38
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,icNF00.10a,cell_lines,Development,PUB41564118,RES42459202,USEae91ad03
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,icNF04.9a,cell_lines,Development,PUB41564118,RES458b9b4f,USE2852c773
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,i28cNF,cell_lines,Development,PUB41564118,RES0be2e415,USE6ec36049
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,i18cNF,cell_lines,Development,PUB41564118,RESa3568ca9,USE85979a13
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,i21cNF,cell_lines,Development,PUB41564118,RESbcad377e,USE7574f924
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,CCD-1112Sk,cell_lines,Experimental Usage,PUB32642733,RES1aa9a303,USE1993ad81
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,Rosetta2(DE3) competent cells,cell_lines,Experimental Usage,PUB24882693,RES40c42020,USE43bbe635
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,ST88-3,cell_lines,Experimental Usage,PUB18483311,RES8fd7beb2,USE3fb648e9
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,T265p21,cell_lines,Experimental Usage,PUB18483311,REScea4eddb,USE5f17dcd4
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,DS-red STS26T cell line,cell_lines,Experimental Usage,PUB18483311,RESe2bfa3a9,USEd939e90a
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,hTERT ipNF05.5,cell_lines,Experimental Usage,PUB37140985,RES487eca0a,USE7bcbf489
PMID:37140985 | PMID:38127282,10.1172/JCI168227 | 10.1158/1078-0432.CCR-23-2548,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,hTERT ipn02.3 2λ,cell_lines,Experimental Usage,PUB5d46f60e,RESe9e677f7,USE74db0992
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,E13.5 DRG neurosphere cells,cell_lines,Experimental Usage,PUB37140985,RES8e44a7c5,USEd916fe40
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Daoy,cell_lines,Experimental Usage,PUB20551058,RES70f6328b,USEf0b95072
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,NF1-/- iPSC-derived neural crest cells,cell_lines,Experimental Usage,PUB38175707,RESc5815f89,USEdd0eb8d3
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,hTERT NF1 ipNF95.6 cell line,cell_lines,Experimental Usage,PUB38127282,RES05f18fad,USE6380c3f3
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF05.5-MX,cell_lines,Experimental Usage,PUB38136356,RES4619f98d,USE2aaa2454
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF95.11b C/T,cell_lines,Experimental Usage,PUB38136356,RES5d59f7d9,USEd30b26e8
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF02.3 2λ,cell_lines,Experimental Usage,PUB38136356,RES0fc58348,USEf172b7fb
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF02.8,cell_lines,Experimental Usage,PUB38136356,RES9e84f002,USE56945ca5
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,NF95.11b,cell_lines,Experimental Usage,PUB38216572,RESf59f8ed8,USEd2c25c40
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,NF95.6,cell_lines,Experimental Usage,PUB38216572,RES250e44b5,USE122962ab
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,SNF94.3,cell_lines,Experimental Usage,PUB38216572,RES920f4fcf,USE012f6371
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,JW18.2,cell_lines,Experimental Usage,PUB38216572,RES9723ccfe,USE144c34f3
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,JW23.3,cell_lines,Experimental Usage,PUB38216572,RES80dcb249,USE3c21bd47
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,KT21-MG1,cell_lines,Experimental Usage,PUB36148553,RESb1b27a6d,USE43f3f9ce
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,293FT,cell_lines,Experimental Usage,PUB36148553,RESd536c7d1,USE1ed2fe58
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype,,NF2 primary fibroblasts,cell_lines,Experimental Usage,PUB36420221,RES33a9f0e9,USE2fba8a68
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,Primary human vestibular schwannoma (VS) cell cultures,cell_lines,Experimental Usage,PUB32438526,RESf476bcb6,USEb49a1d20
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,Primary normal rat Schwann cells,cell_lines,Experimental Usage,PUB18367665,RES4140cd3d,USE27fecbe7
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,ipNF05.5 Mixed Clones,cell_lines,Experimental Usage,PUB40723243,RES21be72dc,USEec71b29b
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,Nf1flox/flox bone marrow stromal cells,cell_lines,Experimental Usage,PUB25043591,RES3e51adf0,USEfd3aab5b
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,DH5α bacteria,cell_lines,Experimental Usage,PUB19144871,RES036a0bbd,USE1f5449a4
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,tail-tip fibroblasts (TTFs),cell_lines,Experimental Usage,PUB28392281,RES642f055b,USE4f4401f3
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Neural stem cells,cell_lines,Experimental Usage,PUB36241865,RES7b2e113f,USE4c7c56c5
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,Nf2-deficient spinal cord neural progenitor cells,cell_lines,Experimental Usage,PUB24817309,RES07add6ac,USEea71ab71
PMID:41001593 | PMID:32948135,10.1080/23723556.2025.2561292 | 10.1186/s12885-020-07397-w,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor. | Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,NSF1,cell_lines,Experimental Usage,PUB05aef37d,RESce5c25bd,USE285fab03
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,BRGN,cell_lines,Experimental Usage,PUB41001593,RES93a28363,USE9e553640
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,primary human Schwann cells (HSC),cell_lines,Experimental Usage,PUB41001593,RESe7efd56d,USE1a2a80bf
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,Normal human Schwann cells (HSC),cell_lines,Experimental Usage,PUB38203448,RES6382be4a,USE6c8cdfc2
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,B8 fibroblasts,cell_lines,Experimental Usage,PUB32948135,RESb987fd97,USE836511e8
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,95.6,cell_lines,Experimental Usage,PUB33658640,RESea197438,USEf1f054e4
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,ipn02.3,cell_lines,Experimental Usage,PUB33658640,RESfd5f7e36,USE82629228
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,cNF-Skindex,clinical_assessment_tools,Experimental Usage,PUB38811427,RES957dce31,USEe5aa7976
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire,clinical_assessment_tools,Development,PUB28193237,RESeffc3820,USEbd1864a7
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Cirrus HD-OCT,clinical_assessment_tools,Experimental Usage,PUB38990917,RESa1301f77,USEb3f6f962
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Teller acuity cards,clinical_assessment_tools,Experimental Usage,PUB38990917,REScf856181,USE1de06c15
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Cardiff acuity cards,clinical_assessment_tools,Experimental Usage,PUB38990917,RES9cacf8bc,USE7ffcebc3
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Lea cards,clinical_assessment_tools,Experimental Usage,PUB38990917,RESdb522b86,USE43b115f7
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,KM (Konstantin Moutakis) cards,clinical_assessment_tools,Experimental Usage,PUB38990917,RES52bd88fc,USE2e311d10
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Humphrey Field Analyzer perimetry,clinical_assessment_tools,Experimental Usage,PUB38990917,RESce67dd2f,USE4fc5e063
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,World Health Organization Categories of Childhood VI scale,clinical_assessment_tools,Experimental Usage,PUB38990917,RESc9cd8d77,USE9af56eba
PMID:40737523,10.2196/71728,Clinician Perspectives of a Magnetic Resonance Imaging-Based 3D Volumetric Analysis Tool for Neurofibromatosis Type 2-Related Schwannomatosis: Qualitative Pilot Study.,,Likert scale questionnaire,clinical_assessment_tools,Experimental Usage,PUB40737523,RES19135a16,USEf1fadf5e
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,BoN (Burden of NF1) questionnaire,clinical_assessment_tools,Development,PUB31053133,RES3d1c5b79,USE6e0c47f0
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,Dermatology Life Quality Index (DLQI),clinical_assessment_tools,Experimental Usage,PUB31053133,RESa9713e90,USE2d089f26
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,SF12,clinical_assessment_tools,Experimental Usage,PUB31053133,RES0f6ab480,USE54dafaa0
PMID:33085177 | PMID:38499890,10.1002/mgg3.1530 | 10.1186/s41687-024-00714-y,"The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas. | The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",,PlexiQoL,clinical_assessment_tools,Development,PUBc472289e,RES6496c902,USEa7153d4e
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,DINs (Deep Interactive Networks),computational_tools,Development,PUB34106871,RESda500560,USEc4be654d
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,RENOVO-NF1,computational_tools,Development,PUB40887659,RES5b11eb44,USE709185ef
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,dLight1.2,genetic_reagents,Experimental Usage,PUB31545171,RES2d71f332,USEffede52d
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,hChR2(H134R)-EYFP,genetic_reagents,Experimental Usage,PUB31545171,RES7f002cca,USE2659cc68
PMID:31545171 | PMID:35589737 | PMID:20200958 | PMID:19191334 | PMID:28392281 | PMID:25772366 | PMID:23685747 | PMID:17924978 | PMID:38127282 | PMID:25043591,10.7554/eLife.48983 | 10.1038/s41467-022-30466-6 | 10.1002/jbmr.42 | 10.1002/glia.20845 | 10.1016/j.expneurol.2017.04.001 | 10.1016/j.celrep.2015.02.041 | 10.1038/ng.2641 | 10.1111/j.1750-3639.2007.00105.x | 10.1158/1078-0432.CCR-23-2548 | 10.1002/jbmr.2316,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1. | Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Human stem cell modeling in neurofibromatosis type 1 (NF1). | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression. | Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,Cre,genetic_reagents,Experimental Usage,PUBfe4823ee,RESd3b0b74a,USE751e0643
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,eNpHR3.0-eYFP,genetic_reagents,Experimental Usage,PUB31545171,RES051bb136,USE575c76f7
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,mCherry,genetic_reagents,Experimental Usage,PUB31545171,RES5fb8675b,USEcedd44f5
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,tTA,genetic_reagents,Experimental Usage,PUB31545171,RESb1a15122,USEa819ace2
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,mRuby,genetic_reagents,Experimental Usage,PUB31545171,RES31ab06c0,USE9d3f5c40
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,mTurquoise,genetic_reagents,Experimental Usage,PUB31545171,RES8a7d11db,USEc3e1280c
PMID:40590220 | PMID:31545171 | PMID:21072183 | PMID:39129390 | PMID:24509877 | PMID:20049725 | PMID:25043591,10.1172/JCI188932 | 10.7554/eLife.48983 | 10.1371/journal.pone.0013791 | 10.1002/1878-0261.13704 | 10.1038/onc.2013.506 | 10.1002/emmm.200900027 | 10.1002/jbmr.2316,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1. | p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,GFP,genetic_reagents,Experimental Usage,PUB93249fad,RESb308811a,USE2c8739b5
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,iCAP-PHP.eB,genetic_reagents,Experimental Usage,PUB31545171,RES74ca0a0c,USE05c52f65
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,dLight1,genetic_reagents,Experimental Usage,PUB31545171,RES7069b02e,USEe2f04970
PMID:32642734 | PMID:19191334 | PMID:25772366,10.1093/noajnl/vdz026 | 10.1002/glia.20845 | 10.1016/j.celrep.2015.02.041,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,LacZ,genetic_reagents,Experimental Usage,PUBaaede3c3,RES1037d2b5,USEc93bf019
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,Trim23,genetic_reagents,Experimental Usage,PUB32642734,RES3662578a,USE8a1d2c61
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,shNF1,genetic_reagents,Experimental Usage,PUB35589737,RESe7247e8c,USE4e5f391d
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,shCOL1A2,genetic_reagents,Experimental Usage,PUB35589737,RES0d91d4ea,USE3ba7551a
PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,pCR2.1-TOPO,genetic_reagents,Experimental Usage,PUB12057013,RES38d2bed4,USEdbb104ac
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,NF1 gRNA,genetic_reagents,Experimental Usage,PUB38216123,RES97ca2fea,USEdc7460f1
PMID:20200958 | PMID:21949590,10.1002/jbmr.42 | 10.2478/v10134-010-0025-8,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts. | ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,eGFP,genetic_reagents,Experimental Usage,PUB65dbf54e,RES14a8b78a,USE3da828ae
PMID:31836666 | PMID:36689660,10.1074/jbc.RA119.010934 | 10.1073/pnas.2208960120,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,NF1 isoform 2,genetic_reagents,Experimental Usage,PUB021451f7,RES4701a839,USE25e855b1
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,truXTRAC FFPE DNA,genetic_reagents,Experimental Usage,PUB36598417,RESfdb6ba4d,USEdb381f39
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,Kapa HyperPlus,genetic_reagents,Experimental Usage,PUB36598417,RES63ecf018,USEa2f5daac
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,HumanMethylationEPIC,genetic_reagents,Experimental Usage,PUB36598417,RESacb583a3,USE8369d12c
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,EZ DNA methylation Gold,genetic_reagents,Experimental Usage,PUB36598417,RESed7ca552,USEfbe33b2e
PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,oligo-dT,genetic_reagents,Experimental Usage,PUB18670322,RESb721c2c2,USEa9b57519
PMID:18670322 | PMID:21726432,10.1097/MLG.0b013e318177e20b | 10.1186/1741-7015-9-82,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors. | MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,PCR master mix,genetic_reagents,Experimental Usage,PUBf0972bee,RES62bd558c,USEc5c408b4
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,GLuc,genetic_reagents,Experimental Usage,PUB30617350,RES8e819d3d,USEf8347dcd
PMID:38216572 | PMID:27956228 | PMID:35789380 | PMID:39415595,10.1038/s41467-024-44755-9 | 10.1053/j.gastro.2016.12.002 | 10.1158/2159-8290.CD-21-1671 | 10.1242/dmm.050862,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. | Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,sgRNA,genetic_reagents,Experimental Usage,PUBd71208a9,RES2bff6dab,USE21fb7612
PMID:33273014 | PMID:29715273 | PMID:30274821 | PMID:26219339 | PMID:24595234,10.1074/jbc.RA120.014960 | 10.1371/journal.pone.0196726 | 10.1016/j.ebiom.2018.09.042 | 10.18632/oncotarget.4858 | 10.1371/journal.pone.0090853,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,NF2,genetic_reagents,Experimental Usage,PUB7332362a,RESc7f2e43a,USE8f87f160
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,apterous-Gal4,genetic_reagents,Experimental Usage,PUB24595234,RESfe394f0d,USEb31ad1db
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,H-RAS,genetic_reagents,Experimental Usage,PUB40225167,RES7663bdf6,USE1b8f39f8
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,SPRED1,genetic_reagents,Experimental Usage,PUB40225167,RESc85d1396,USE7e985367
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,RAF-RBD,genetic_reagents,Experimental Usage,PUB40225167,RESd888775d,USE20740cf8
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,BNIP3,genetic_reagents,Experimental Usage,PUB24824755,RES0342e628,USE2020d96e
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,HIF-1α,genetic_reagents,Experimental Usage,PUB24824755,RESd76e0e6e,USE57bfa9bb
PMID:32461556 | PMID:38481529 | PMID:39890807 | PMID:34646065 | PMID:37446790 | PMID:34011935 | PMID:29670214 | PMID:37140985 | PMID:36241865,10.1038/s41467-020-16432-0 | 10.3389/fcell.2024.1359561 | 10.1038/s41598-024-84493-y | 10.1155/2021/9386823 | 10.3390/molecules28135128 | 10.1038/s41419-021-03802-9 | 10.1038/s41598-018-24310-5 | 10.1172/JCI168227 | 10.1038/s12276-022-00850-9,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1. | Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism. | Survival and | Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine. | Restoring functional neurofibromin by protein transduction. | Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Nf1,genetic_reagents,Experimental Usage,PUB01669d95,RES5b74c968,USE2bd316c5
PMID:39269317 | PMID:34415582 | PMID:34630515 | PMID:37164978 | PMID:32642733 | PMID:39129390 | PMID:39890807 | PMID:41036607 | PMID:41023593,10.1158/1078-0432.CCR-24-1750 | 10.1002/glia.24075 | 10.3389/fgene.2021.721045 | 10.1038/s41467-023-38432-6 | 10.1093/noajnl/vdz061 | 10.1002/1878-0261.13704 | 10.1038/s41598-024-84493-y | 10.1158/1535-7163.MCT-24-1053 | 10.1186/s10020-025-01353-9,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury. | Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism. | Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors. | Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,Cas9,genetic_reagents,Experimental Usage,PUBbd3dc5e0,RES1b294e26,USEa604c910
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and,,PrimeSTAR GXL,genetic_reagents,Experimental Usage,PUB34630515,RESb0129c8a,USE99cd86e8
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,NHE1,genetic_reagents,Experimental Usage,PUB32457840,RESbdfd2ddc,USEa3497740
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,Merlin,genetic_reagents,Experimental Usage,PUB32457840,RES11f352ff,USE90bdb38d
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,V-CSCW2,genetic_reagents,Experimental Usage,PUB33273014,RES5991d509,USEde954290
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,MM-121,genetic_reagents,Experimental Usage,PUB33273014,RES77d62ff2,USE615bd9fd
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,SA3,genetic_reagents,Experimental Usage,PUB38502231,RESbc8cc751,USEa7b62880
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,GRDC24,genetic_reagents,Development,PUB41022755,RES98550cd1,USE76908752
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,NF-targeting capsid,genetic_reagents,Development,PUB41022755,RES508e038b,USEbc136cb4
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,Human Phospho-RTK Array,genetic_reagents,Experimental Usage,PUB39269317,RES35408b12,USE9b84cd1a
PMID:39269317 | PMID:39129390 | PMID:35393510,10.1158/1078-0432.CCR-24-1750 | 10.1002/1878-0261.13704 | 10.1038/s41418-022-00991-4,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,CRISPR-Cas9,genetic_reagents,Experimental Usage,PUBd1458709,RESb9653fa2,USE1d73be90
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,Guide RNA,genetic_reagents,Experimental Usage,PUB39269317,RES7892bc60,USE7c0c6ffc
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,dNf1,genetic_reagents,Experimental Usage,PUB39129390,RESdcd0e8c4,USEf1fa606e
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,Human All Exon capture probes,genetic_reagents,Experimental Usage,PUB30531922,RES8454337b,USE726575d1
PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,,Fluc and mCherry,genetic_reagents,Experimental Usage,PUB21111000,RES4e80b0f7,USEf852552a
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,L-[18F]FETrp,genetic_reagents,Experimental Usage,PUB38931352,REScd62db3c,USE2f42ecdc
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,PDLIM2 shRNA,genetic_reagents,Experimental Usage,PUB28126595,RES5d6244ac,USEd6f4201b
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,λ-phosphatase,genetic_reagents,Experimental Usage,PUB28126595,RESc32e5f74,USE53a87d81
PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,Cre and gRNAs,genetic_reagents,Development,PUB39996452,RESfe7916fc,USEa8234e62
PMID:29715273 | PMID:32438526,10.1371/journal.pone.0196726 | 10.1002/lary.28671,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,empty vector,genetic_reagents,Experimental Usage,PUB40c95ee8,RES9b874e05,USE4d4bdeae
PMID:24509877 | PMID:35393510 | PMID:16835260 | PMID:38000020,10.1038/onc.2013.506 | 10.1038/s41418-022-00991-4 | 10.1093/hmg/ddl165 | 10.1126/sciadv.adg8876,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD | Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. | CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,NF1-GRD,genetic_reagents,Experimental Usage,PUB5de229dd,RESe1af3877,USEa0c1f278
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,MAF,genetic_reagents,Experimental Usage,PUB24509877,RES747f90be,USE3dd4e361
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,MAF ORF,genetic_reagents,Experimental Usage,PUB24509877,RESbb6fa284,USE69f94c7b
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,Tet-On,genetic_reagents,Experimental Usage,PUB24509877,RES15a9cf58,USE6d8b9276
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,AP-1 luciferase,genetic_reagents,Experimental Usage,PUB24509877,RESa1092b09,USE5a6d940e
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,pLKO.1,genetic_reagents,Experimental Usage,PUB23328114,RESdf9ab1bb,USE5f57b47a
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,shRHAMM,genetic_reagents,Experimental Usage,PUB23328114,RES2f759dfb,USE8868aa45
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,shTPX2,genetic_reagents,Experimental Usage,PUB23328114,RESff1be36a,USE2187ef79
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,ZEB1,genetic_reagents,Experimental Usage,PUB36322658,RES57e3d7c5,USE5f759baf
PMID:36322658 | PMID:36148553,10.1126/sciadv.abo5442 | 10.1093/brain/awac342,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,ALDH1A1,genetic_reagents,Experimental Usage,PUBb6e40540,RES7b3e5bd7,USE89ab77b7
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,StrepII tag,genetic_reagents,Experimental Usage,PUB39890807,RESc43f717a,USE2ac28ed3
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,M-PER,genetic_reagents,Experimental Usage,PUB39890807,RES0ba17ee2,USE8eb92b35
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,BCA,genetic_reagents,Experimental Usage,PUB39890807,RES0680f2a2,USEab5ae207
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,NF1-targeting TALEN,genetic_reagents,Experimental Usage,PUB37520682,RES17bd5adf,USE3186b6ad
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,Gentamicin,genetic_reagents,Experimental Usage,PUB37520682,RES72375016,USEa8a1388f
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,NF1 DLR,genetic_reagents,Experimental Usage,PUB37520682,RES635b74af,USEcfa1dec4
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,PBSB,genetic_reagents,Experimental Usage,PUB37520682,RES5b367951,USEede0adff
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,UPF1,genetic_reagents,Experimental Usage,PUB37520682,RES820a3434,USEff111dd4
PMID:40684195 | PMID:34040258 | PMID:34010628,10.1186/s40478-025-02075-z | 10.1038/s41586-021-03580-6 | 10.1016/j.stem.2021.04.029,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,EdU,genetic_reagents,Experimental Usage,PUB482dfbb5,RESa77ce9e5,USEef49c7bf
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,Lipofectamine,genetic_reagents,Experimental Usage,PUB21949590,RESa2ad8ee9,USE3eae0fcb
PMID:35789380 | PMID:26219339 | PMID:23685747 | PMID:41023593 | PMID:25772366,10.1158/2159-8290.CD-21-1671 | 10.18632/oncotarget.4858 | 10.1038/ng.2641 | 10.1186/s10020-025-01353-9 | 10.1016/j.celrep.2015.02.041,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,shRNA,genetic_reagents,Experimental Usage,PUB61dc23a1,RESe38e3fc5,USEa9705c32
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,hGFAP-cre,genetic_reagents,Experimental Usage,PUB22901811,RESf7cc34f2,USE493f973c
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,Nf1 flox,genetic_reagents,Experimental Usage,PUB22901811,RESc54d4fe5,USE8feefad9
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,Nf1 KO,genetic_reagents,Experimental Usage,PUB22901811,RES42a9482e,USEa913495c
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,Nestin-cre ER,genetic_reagents,Experimental Usage,PUB22901811,RES32a088fa,USE75e14b15
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,R26 LacZR,genetic_reagents,Experimental Usage,PUB22901811,RES5e26f1a8,USEcc5b9470
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,human neurofibromin,genetic_reagents,Experimental Usage,PUB40590220,RES3c86e21c,USE00e1c30f
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,human FBXW11,genetic_reagents,Experimental Usage,PUB40590220,RES5783b081,USE765141e7
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,Cre-GFP,genetic_reagents,Experimental Usage,PUB40590220,RESad01da66,USE8669b7c3
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,NF1 capture probes,genetic_reagents,Experimental Usage,PUB27999334,RESb42186d8,USE3754d4f7
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,Human All Exon,genetic_reagents,Experimental Usage,PUB25549701,RES94c0f4e7,USE7a34b633
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,targeted region arrays,genetic_reagents,Experimental Usage,PUB25549701,RES77e25315,USE14eb56c7
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,COMT val158met probe,genetic_reagents,Experimental Usage,PUB27458360,RES101c52a5,USEe2073d51
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,nuclear RFP,genetic_reagents,Experimental Usage,PUB36730269,RES3b400750,USE3db5a29a
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,neurofibromin 2,genetic_reagents,Experimental Usage,PUB20195187,RESf228eeaf,USE06646844
PMID:20195187 | PMID:33032988,10.1097/MAO.0b013e3181d2777f | 10.1158/0008-5472.CAN-20-1365,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,non-targeting control,genetic_reagents,Experimental Usage,PUB3ce1a0b1,REScb34c5cc,USEe18825a2
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,Ras Binding Domain,genetic_reagents,Experimental Usage,PUB18413802,RESa52ab452,USE7b61cbaa
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,B-Raf,genetic_reagents,Experimental Usage,PUB18413802,RES8722aa27,USEc7f9ee6a
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,C-Raf,genetic_reagents,Experimental Usage,PUB18413802,RESe7f27bc5,USE680a3ea7
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,NF2 shRNA,genetic_reagents,Experimental Usage,PUB30274821,RES0c4385ea,USEb00bc68a
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,P53 shRNA,genetic_reagents,Experimental Usage,PUB30274821,RES0fa626bc,USE5df83b33
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,P53,genetic_reagents,Experimental Usage,PUB30274821,RESc66f3b31,USEc76f4f7d
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,CXCL12,genetic_reagents,Experimental Usage,PUB20554030,RESc421f3ce,USE0487af63
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,firefly luciferase-GFP fusion,genetic_reagents,Experimental Usage,PUB20554030,RESf0cdca20,USE86d88dc7
PMID:28831766,10.1007/s12104-017-9768-1,NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.,,Spred1(EVH1),genetic_reagents,Experimental Usage,PUB28831766,RES66e53bd9,USE3e31d8bf
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,FLAG,genetic_reagents,Experimental Usage,PUB36689660,RESdaa80ae1,USE0a84e4c5
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,HA,genetic_reagents,Experimental Usage,PUB36689660,RES34045619,USE7adf27bb
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,Tet-inducible,genetic_reagents,Experimental Usage,PUB36689660,RES82ed4d69,USEc2a44e4e
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,packaging,genetic_reagents,Experimental Usage,PUB36689660,RES13b05979,USE9a69a7e2
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,envelope,genetic_reagents,Experimental Usage,PUB36689660,RESd2303a47,USE9bb83605
PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,DNA capture system,genetic_reagents,Experimental Usage,PUB32107864,RESa7b33b2e,USEd4f97200
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,Tet-pLKO-puro,genetic_reagents,Experimental Usage,PUB38000020,RESa56acf38,USE5fe02569
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,TTIGFP-MLUEX,genetic_reagents,Experimental Usage,PUB38000020,RES53553b99,USEedaa0695
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,shPTPN11,genetic_reagents,Experimental Usage,PUB38000020,RES4b3aca2c,USE0c28d8d1
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,SB11,genetic_reagents,Experimental Usage,PUB23685747,RES75951cad,USE8b815cd7
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,T2/Onc15,genetic_reagents,Experimental Usage,PUB23685747,RESd71af387,USEbe798643
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,EGFR,genetic_reagents,Experimental Usage,PUB23685747,RES8bac7882,USE3e7ed760
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,FOXR2,genetic_reagents,Experimental Usage,PUB23685747,RES7441e07c,USEe539f675
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,HPRT,genetic_reagents,Experimental Usage,PUB23685747,RES537c99bb,USE1e56b10d
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,KCNMA1,genetic_reagents,Experimental Usage,PUB38907342,RES8b3eb9e0,USE721a9e17
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,PRKCE,genetic_reagents,Experimental Usage,PUB38907342,RES04bb8752,USE7f85a7b4
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,OPCML,genetic_reagents,Experimental Usage,PUB38907342,RESfd2a9c90,USE86acce71
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,GRIK2,genetic_reagents,Experimental Usage,PUB38907342,RES80efe2ec,USE76b68e66
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,CADM2,genetic_reagents,Experimental Usage,PUB38907342,RES65c51cf7,USE9858f484
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,CREB5,genetic_reagents,Experimental Usage,PUB38907342,RES9e76981a,USEbf833b89
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,CAMK1D,genetic_reagents,Experimental Usage,PUB38907342,RESc1705075,USE754cf298
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,ITGB8,genetic_reagents,Experimental Usage,PUB38907342,RESd2d95a42,USEae36d564
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,Klenow (exo-),genetic_reagents,Experimental Usage,PUB35244537,RESad653dc1,USE4915a497
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,anti-HER1 CAR 806,genetic_reagents,Development,PUB40025578,RESfa274add,USE76c3f0d3
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,anti-HER1 CAR E2,genetic_reagents,Development,PUB40025578,RESb5824254,USE61a1a550
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,anti-HER1 CAR NEC,genetic_reagents,Development,PUB40025578,RES201f8b36,USE40062199
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,AHR,genetic_reagents,Experimental Usage,PUB34011935,REScae79a31,USE8a97eb97
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,gRNA,genetic_reagents,Experimental Usage,PUB41036607,RES112d33ff,USEfa0e6f4b
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,Luciferase-IRES-GFP,genetic_reagents,Experimental Usage,PUB41036607,RESe51e6fc7,USE1878f56e
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,PB7 transposase,genetic_reagents,Experimental Usage,PUB41036607,RES19a5ca87,USE33b34481
PMID:24980480,10.1186/1479-7364-8-10,Novel age-dependent targets in vestibular schwannomas.,,Human Universal Reference RNA,genetic_reagents,Experimental Usage,PUB24980480,RES0828ec0e,USE59d00b25
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,SGK1,genetic_reagents,Experimental Usage,PUB26219339,RES2cea53d0,USE8c167bda
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,PAK1,genetic_reagents,Experimental Usage,PUB26219339,RES03d91c64,USEa05263c0
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,RHEB,genetic_reagents,Experimental Usage,PUB26219339,RES26840da8,USEcb6e2123
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,Ultra Low Cluster Plates,genetic_reagents,Experimental Usage,PUB25026211,RESa7f249ae,USEf595acf3
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,GST-PID,genetic_reagents,Experimental Usage,PUB21072183,RES125af38d,USE5f1cf706
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,Gst-PID L107F,genetic_reagents,Experimental Usage,PUB21072183,RES31f47e0c,USE5c3e6cf9
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,PTPN11,genetic_reagents,Experimental Usage,PUB33032988,RES12f322ef,USE24f1e061
PMID:28051113 | PMID:36420221,10.1038/srep39348 | 10.1016/j.omtn.2022.10.026,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape. | Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype",,I2HCP panel,genetic_reagents,Development,PUB3089a41c,RESa32cfd07,USE2097e1c0
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,shRNAs,genetic_reagents,Experimental Usage,PUB26904939,RES33f252d2,USE7f39f56f
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,β-catenin ΔN90,genetic_reagents,Experimental Usage,PUB26904939,RES1cd7b3a7,USE44aa70fe
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,D22S193,genetic_reagents,Experimental Usage,PUB18974932,RES8d1863d3,USE0a9b2931
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,NF2 TET,genetic_reagents,Experimental Usage,PUB18974932,RES23ac5668,USE83ba05b6
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,D22S929,genetic_reagents,Experimental Usage,PUB18974932,RES977350e7,USEc5f011cc
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,D22S268,genetic_reagents,Experimental Usage,PUB18974932,RESd9935604,USE5b8b105e
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,D22S430,genetic_reagents,Experimental Usage,PUB18974932,RESe6f59aa8,USE437552eb
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,BstUI,genetic_reagents,Experimental Usage,PUB18974932,RES7e1b1c54,USE52921354
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,biocytin,genetic_reagents,Experimental Usage,PUB25917366,RES91c49110,USE1feeec64
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,NucLight red,genetic_reagents,Experimental Usage,PUB38714355,RESf210d6cb,USE174c887f
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,HumanOmni2.5-8,genetic_reagents,Experimental Usage,PUB28398289,RES6ab36ca5,USEf231816e
PMID:36420221 | PMID:29670214,10.1016/j.omtn.2022.10.026 | 10.1038/s41598-018-24310-5,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype | Restoring functional neurofibromin by protein transduction.,,Endo-Porter,genetic_reagents,Experimental Usage,PUB4b8b6676,RES3d4dd558,USEdd6a42a9
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,interferon alpha-2b,genetic_reagents,Experimental Usage,PUB28256556,RESb17781f7,USE08fb61e1
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,shSOX9,genetic_reagents,Experimental Usage,PUB20049725,RES67b7afec,USE69b6a11d
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,hTERT and mCdk4,genetic_reagents,Experimental Usage,PUB41564118,RES433a48c9,USE688e6250
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,hTERT,genetic_reagents,Experimental Usage,PUB41564118,RES6de26181,USEd0335e29
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,mCdk4,genetic_reagents,Experimental Usage,PUB41564118,RESc2677df1,USE593d901d
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,KIF15/KIF23 siRNA,genetic_reagents,Experimental Usage,PUB32642733,RES81f2af23,USE9c3104a4
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,RGS2,genetic_reagents,Experimental Usage,PUB32642733,RES5054f463,USE34d71374
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,ispinesib,genetic_reagents,Experimental Usage,PUB32642733,RES2cfb93d4,USE0bdb9d1e
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,Merlin isoform 1,genetic_reagents,Experimental Usage,PUB24882693,RES23b2c1c0,USE320f9c20
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,Merlin(S518D) and Merlin(S518E) mutants,genetic_reagents,Experimental Usage,PUB24882693,RES2f3f2a53,USE18ab2e9a
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,HiTrap Chelating Sepharose™ High Performance,genetic_reagents,Experimental Usage,PUB24882693,RES69d1dc1f,USE65fe4307
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,Superdex 200 10/300 GL column,genetic_reagents,Experimental Usage,PUB24882693,RESfb6ee92d,USE489477ea
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,Gd-DTPA,genetic_reagents,Experimental Usage,PUB17924978,RES9541c9a5,USE02291911
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,Human Mapping 100K Set,genetic_reagents,Experimental Usage,PUB25003081,RES64881225,USE54c0bd63
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,GeneChip Human Genome U133 Plus 2.0 Arrays,genetic_reagents,Experimental Usage,PUB25003081,RESd6c8e47e,USE58148beb
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,PDE4A1,genetic_reagents,Development,PUB20551058,RESc1550c66,USEed98ec46
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,PDE4A1-H229Q,genetic_reagents,Development,PUB20551058,RES1bcd1793,USE728a11f6
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,firefly luciferase-eGFP fusion,genetic_reagents,Experimental Usage,PUB20551058,RES50652e79,USE312ae02b
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,PAM71,genetic_reagents,Experimental Usage,PUB38175707,RES4f7ce1c9,USEb1a077ca
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,Microsatellite markers,genetic_reagents,Experimental Usage,PUB33025139,RESb587ac38,USE3aee968f
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,MLPA probe set,genetic_reagents,Experimental Usage,PUB33025139,RES1bc23576,USE132b2f7c
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of",,Kit Ligand,genetic_reagents,Experimental Usage,PUB31527226,RES0e1b9219,USE7630c973
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,dCas9-BFP-KRAB,genetic_reagents,Experimental Usage,PUB38216572,RES62860313,USE2f93a075
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,TAZ,genetic_reagents,Experimental Usage,PUB36148553,RESb80433db,USE96418cbf
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,YAP,genetic_reagents,Experimental Usage,PUB36148553,RES593ff8fa,USE4bf95dde
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Scramble,genetic_reagents,Experimental Usage,PUB36148553,RESae8f2761,USE65fdee16
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,Merlin siRNA,genetic_reagents,Experimental Usage,PUB25043298,RESf0456171,USE830c0184
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,HA-Merlin,genetic_reagents,Experimental Usage,PUB25043298,RESd9daee7e,USEb485833f
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,S518A HA-Merlin,genetic_reagents,Experimental Usage,PUB25043298,RES7ba0612d,USEf471b8ec
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,IPA-3,genetic_reagents,Experimental Usage,PUB25043298,RES32935ef7,USEa8124903
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype,,PMOs,genetic_reagents,Experimental Usage,PUB36420221,RES35f1da9f,USE0fda74b3
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype,,Gateway Gene Cloning system,genetic_reagents,Experimental Usage,PUB36420221,RES8e3daffb,USE1223f8e8
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype,,FLAG Tag,genetic_reagents,Experimental Usage,PUB36420221,RESba333718,USEaabab88e
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype,,Lipofectamine LTX,genetic_reagents,Experimental Usage,PUB36420221,RESd573c252,USEc73d36a7
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,NeuroD1,genetic_reagents,Experimental Usage,PUB32438526,RES2948591f,USE4e621e1d
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,WC-10,genetic_reagents,Experimental Usage,PUB21963652,RES98dd9a00,USE4e269204
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,telomere repeat sequence probe,genetic_reagents,Experimental Usage,PUB31462295,RESae4ff0e7,USE479fd2d1
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,centromeric DNA repeats probe,genetic_reagents,Experimental Usage,PUB31462295,RESbe191704,USE8023bc4c
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,644 cancer gene panel,genetic_reagents,Experimental Usage,PUB31462295,RESd90674c8,USE493bbf46
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,Human Exome,genetic_reagents,Experimental Usage,PUB24932921,RESfad43e3a,USE09f0925e
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,pcDNA3.1,genetic_reagents,Experimental Usage,PUB24932921,RES1d7de0f3,USEc7b476ae
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,nf2a/b-4sgRNA,genetic_reagents,Experimental Usage,PUB39415595,RES39306a69,USE8b7fe087
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,DUSP6,genetic_reagents,Experimental Usage,PUB33978635,RES2bf6be74,USEbc3bd3f1
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,FOS,genetic_reagents,Experimental Usage,PUB33978635,RES01d9e851,USE9b306aed
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,Tp53,genetic_reagents,Experimental Usage,PUB24371224,RES50cd0dfe,USEf34e1d9b
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,miR34a,genetic_reagents,Experimental Usage,PUB24371224,RES4c563e63,USE1e60f71f
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,PHA,genetic_reagents,Experimental Usage,PUB34782607,RES9591bf70,USEfbeb25ae
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,IL-2,genetic_reagents,Experimental Usage,PUB34782607,RES68caf748,USEb8df59d0
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,MBP fusion,genetic_reagents,Experimental Usage,PUB19144871,RES704417e9,USE56e9fa06
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,His-p55,genetic_reagents,Experimental Usage,PUB19144871,RES6e71737e,USE28f49ac4
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,REPLI-g FFPE,genetic_reagents,Experimental Usage,PUB23071067,RES9e9c93db,USE5d5d37e8
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,reprogramming factors,genetic_reagents,Experimental Usage,PUB28392281,RES29ce008d,USE43167c48
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,"OCT4, SOX2, MYC, KLF4, NANOG, LIN28",genetic_reagents,Experimental Usage,PUB28392281,RES89d9331a,USEc9d6676a
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,1276P NF1 GRD,genetic_reagents,Experimental Usage,PUB16835260,RESdfd13d05,USE94620d73
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,pac,genetic_reagents,Experimental Usage,PUB16835260,RES261f16c0,USE9b8196cb
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,c-abl siRNA,genetic_reagents,Experimental Usage,PUB16835260,RES8db4245e,USEeb999aa2
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,Scrambled siRNA,genetic_reagents,Experimental Usage,PUB16835260,RES67c32bef,USEde25e878
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Rictor,genetic_reagents,Experimental Usage,PUB36241865,RES3875d4d9,USE4fbdf138
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,TUNEL,genetic_reagents,Experimental Usage,PUB36241865,RES3aedacc0,USEee857e58
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,MSCV,genetic_reagents,Experimental Usage,PUB24817309,RES61413661,USE0ae60f00
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,Rac1 N17,genetic_reagents,Experimental Usage,PUB24817309,RESec3d1b0e,USEd6a90b2c
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,PLKO,genetic_reagents,Experimental Usage,PUB24817309,RES2a762eb6,USE8e5ea6ea
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,Custom gene panel,genetic_reagents,Experimental Usage,PUB41001593,RES9b4eb071,USE61da4b52
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,Alexa Fluor 594-labeled dextrans,genetic_reagents,Experimental Usage,PUB26190969,RES5279b0f4,USEd4a69993
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,CEP 8 (D8Z2),genetic_reagents,Experimental Usage,PUB33591953,RES96d1e455,USEed7d9184
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,LSI MYC,genetic_reagents,Experimental Usage,PUB33591953,RESf4121132,USEbde483ef
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,PSME3,genetic_reagents,Experimental Usage,PUB32948135,RES1a0a918e,USEfc656542
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,Cas9 and sgRNAs targeting Nf1+Cdkn2a,genetic_reagents,Experimental Usage,PUB37410426,RES0829546a,USEaf0a56af
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,Ref-1,genetic_reagents,Experimental Usage,PUB33658640,RESb75f9189,USEfb7014b8
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,STAT3,genetic_reagents,Experimental Usage,PUB33658640,RES7b8cfac6,USEe41d632c
PMID:41022755 | PMID:38000020 | PMID:33032988,10.1038/s41467-025-63619-4 | 10.1126/sciadv.adg8876 | 10.1158/0008-5472.CAN-20-1365,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2-002,patient_derived_models,Experimental Usage,PUB7f382a9c,RES16a23407,USE4078078e
PMID:41022755 | PMID:38000020 | PMID:33032988,10.1038/s41467-025-63619-4 | 10.1126/sciadv.adg8876 | 10.1158/0008-5472.CAN-20-1365,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2-031,patient_derived_models,Experimental Usage,PUB7f382a9c,RESdf3c4127,USE6b6aa78e
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,JH-2-079c PDX,patient_derived_models,Experimental Usage,PUB38000020,RES0443ac87,USEfcedb4cb
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,WU-225 PDX,patient_derived_models,Experimental Usage,PUB38000020,RES537ef440,USE4b3fc7fb
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,WU-386 PDX,patient_derived_models,Experimental Usage,PUB38000020,RES9e22d7dd,USE12745c6d
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,WU-545 PDX,patient_derived_models,Experimental Usage,PUB38000020,RES9e54235e,USEb6f73454
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,MN-2 PDX,patient_derived_models,Experimental Usage,PUB38000020,RES0009d5c2,USE3e20e56c
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,MN-3-002 PDX,patient_derived_models,Experimental Usage,PUB38000020,RES3bee3866,USE0cb26c19
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,Patient-derived xenograft (PDX) MPNST model,patient_derived_models,Experimental Usage,PUB41036607,RES1c4e8ce2,USEb415bf6c
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-SP-01 PDOX,patient_derived_models,Experimental Usage,PUB35511749,RESf0162f34,USE6a3eda3b
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-NF1-09 PDOX,patient_derived_models,Experimental Usage,PUB35511749,RESdd3ae49a,USEab54bb06
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,vestibular schwannoma xenografts,patient_derived_models,Experimental Usage,PUB18636037,RES458f9b63,USE6908e058
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2–009,patient_derived_models,Experimental Usage,PUB33032988,RESc49f4ec1,USEafa31a0b
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2–055,patient_derived_models,Experimental Usage,PUB33032988,RES4fff48c1,USE00c65be0
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2–060,patient_derived_models,Experimental Usage,PUB33032988,RES018791d0,USE550e5099
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2–074,patient_derived_models,Experimental Usage,PUB33032988,RESdd043a79,USE5fe1a34a
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2–077,patient_derived_models,Experimental Usage,PUB33032988,RES8cd0e8db,USE2d6f96f8
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,Cutaneous neurofibroma samples,patient_derived_models,Experimental Usage,PUB38744290,RES467d7d57,USE89461185
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,human neurofibroma xenografts,patient_derived_models,Experimental Usage,PUB15240917,RES09dbe9c5,USEca810e3b
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,RHT-92,patient_derived_models,Experimental Usage,PUB33658640,RES8f664fbf,USEcc1c0721
